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SWI mIP sequenses in a hypertensive patient admitted with TIA documenting microbleeds in the basal ganglia area; 
DWI confirmed an acute ischemic lacunar lesion.
Image from Røntgenafdelingen, Bispebjerg Hospital, Copenhagen, Denmark.
One in six adults suffer a stroke during their lifetime and stroke remains the major 
cause of new onset disability in adulthood. The worldwide burden of stroke is increas-
ing due to an ageing population, however, globally half of stroke victims are young.
Stroke is the clinical diagnosis of an acute vascular incident and covers a multitude 
of pathophysiological causes. The clinician needs imaging to make decisions on 
acute treatment as well as to plan a secondary prevention strategy: a non-contrast 
CT and a Duplex of the carotids followed by an aspirin as a one-size-fits-all strategy 
does not always provide sufficient support for those decisions.
Presently, fast, generally available, and non-invasive imaging provides new possibil-
ities of establishing a cause of stroke, and provides specific information on the brain 
parenchyma – including possibly salvageable tissue and micro-bleeds – as well as 
allowing for more specific prognostication in acute stroke. 
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This eBook covers both ischemic and haemorrhagic stroke and includes hot topics 
such as micro-bleeds, salvageable tissue and spot-sign, clinically challenging issues 
including movement artefacts in MRI as well as an overview of present options 
including pragmatic and feasible suggestions for an approach to state of the art 
acute imaging.
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Editorial on the Research Topic
Imaging in Acute Stroke—New Options and State of the Art
During the last two decades, the state of art imaging in acute stroke has developed from non-contrast 
CT performed within 7  days to including hyperacute imaging including both angiographic and 
perfusion imaging. This includes using both new techniques but also using new ways to combine 
long existing modalities in daily practice. The increasing focus on the importance of both swift and 
reliable diagnostics combined with an improved scanner accessibility has fueled this development.
This development in imaging has answered to the needs of the introduction of acute vascular 
recanalization treatments in ischemic stroke, which has revolutionized the area. I.V. thrombolysis 
has been increasingly used since the end of the 1990s and is now considered a standard treatment, 
while mechanical thrombectomy has been accepted as a standard procedure following randomized 
controlled trials documenting its efficacy within the last 5  years. Further, efficacious treatment 
options in acute ICH are sought, including thrombostatics to reduce final hematoma volume lead-
ing to increased activity in this area also.
The imaging modalities, which are in widespread use in primary stroke imaging—at least in 
tertiary centers, include CT, MRI, and sonography. These methods are complementary in clinical 
practice with their different strengths. In the following, we will discuss generally available methods 
to image brain parenchyma, cerebral, and pre-cerebral vasculature and cerebral perfusion in acute 
stroke.
iMaGiNG tHE BraiN ParENCHYMa
Time is of the essence in the diagnosis and treatment of acute ischemic stroke (1). It has been shown 
that by using a CT-based set-up for IV thrombolysis, a door to needle time around 20 min is achiev-
able based on admitting patients directly to hospital units providing imaging facilities including 
radiology department, emergency rooms, or trauma centers (2).
CT has a high sensitivity in detecting blood and thereby identifying a bleeding in the brain 
parenchyma, which is the major contraindication in IV thrombolysis as well as identifying, 
e.g., neoplasms. Consequently, IV thrombolysis can be initiated safely based on a non-contrast-CT 
of the brain as only brain imaging (3).
It has been reported that dual-energy CT (DECT-CT) should improve detection of underly-
ing causes for ICH as well as the differentiation between blood and leaked iodine contrast after 
endovascular procedures compared to standard non-contrast CT.
Trans cranial Doppler (TCD) has little use in visualizing brain parenchyma but can be used to 
measure the size of an intracerebral hemorrhage and thus visualize an eventual expansion in size (4); 
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however, the sensitivity for, e.g., hemorrhage in proximity to the 
scull base does not allow for this modality as only imaging before 
revascularisation treatment.
MRI is superior to CT in showing acute ischemic changes in 
the brain parenchyma (5). Diffusion-weighted imaging shows 
the ischemic lesion in 80–90% of cases in acute stroke but, 
in the remaining patients, there will not be DWI-positivity, 
i.e., the DWI-negative stroke (6). Consequently, a reliable diagno-
sis of stroke cannot be made based on only MRI conformation if 
ischemia, clinical diagnosis is still needed.
The ability to detect ischemic lesions is, however, also valuable 
in transient ischemic attack (TIA). This diagnosis is in Europe 
based on clinical definitions, but severity scores are used in com-
bination with DWI-positivity in the identification of high-risk 
patients who have a substantial risk of a subsequently ischemic 
stroke (7). An unexplained sevenfold variation exists in the fre-
quency of DWI lesions between TIA cohorts, and a DWI-negative 
scan is very far from ruling out a true ischemic event in these 
patients (8). MRI is also superior in identifying the underlying 
cause of stroke based on examination of the brain parenchyma: 
the pattern of DWI lesions helps to differentiate between large 
vessel disease and cardiac emboli where, in the latter, several 
vascular territories are often affected. Microvascular changes in 
small vessel disease can be diagnosed and quantified, not only 
forming the basis of a diagnosis of small vessel disease but also in 
differencing between probable cerebral amyloid angiopathy and 
deep perforator angiopathy. MRI allows for identifying location 
and number of micro bleeds, lacunar infarcts, unspecific vascular 
gliosis, and enhanced perivascular space.
Substantial leukoariosis predict a higher risk of both symp-
tomatic and asymptomatic hemorrhage after IV thrombolysis 
treatment and independent of this was evaluated by MRI or CT 
(9). The presence of cerebral micro-bleeds before IV thrombolysis 
treatment predicts and increased risk of new micro-bleeds after 
treatment. Further, patients with new micro-bleeds were more 
likely to develop symptomatic remote hemorrhage, but no 
increase in rate of hemorrhagic transformation was observed, 
consequently, this is of minor clinical importance (10).
Using MRI in the work-up of hyperacute stroke increases the 
door to needle time with about 10 min even in a well-organized 
setting. This is due to MRI safety issues as well as longer scan-
time compared to CT (11). A protocol used for evaluating acute 
ischemia must include T2 flair and a hemo-sequence in order to 
exclude intracerebral bleeding. MRI is not possible in a substan-
tial number of acute stroke patients due to either safety issues, 
being unable to cooperate, or in need of close monitoring. The 
number of patients falling into this category has been reported 
as high as 20–40% (12) MRI is performed without applying any 
radiation to the patient in comparison with CT, which makes it 
safer to use regarding younger patients.
iMaGiNG tHE artErial VESSElS oF 
tHE HEad aNd NECK
By adding CT-angiography (CTA) to an nc-CT, the vessels from 
the aortic arch to the vertex can be visualized with a resolution 
of 0.5  mm iso voxel corresponding to a vessel size of 1  mm. 
This reveals vessel occlusion down to vessel sized too small 
for mechanical thrombectomy, thereby allowing for precise 
identification of patients for this procedure. CTA is also reliable 
in evaluation for underlying pathologies such as dissection and 
arteriosclerotic disease (13, 14).
CT-angiography in combination with cerebral post-contrast 
CT is not only a strong tool in identification of neoplasms but also 
other underlying causes in patients with intracerebral hemor-
rhage, including some vascular malformations (15). In addition, 
the presence of arterial and/or venous extravasation of contrast, 
the so-called spot-sign, is a strong predictor for hematoma 
expansion with resulting poorer outcome (16). This may be of 
use in selecting patients for experimental treatment with pro-
thrombotic drugs in order to reduce hematoma expansion (16).
Dual-energy CT improves the diagnostic accuracy of CTA 
in areas close to bone (17), which is clinically highly relevant in 
patients with posterior circulation stroke.
Sonography can be performed in the stroke unit and, since it 
involves no radiation exposure, patient safety issues will not limit 
the number of examinations. It is possible to evaluate both arte-
rial vessels of the neck as well as intracranial vessels—the latter 
only as a flow examination whereas the vessel wall of the arteries 
of the neck can be examined with a resolution of 0.2 mm. This 
allows the detection of occlusions and stenosis as by CTA but 
with a greater possibility of a non-conclusive examination based 
on the possible lack of a temporal sonar window or other bone 
disturbances of the sonar signal. TCD allows for documentation 
of reperfusion after IV thrombolysis treatment (18) as well as for 
quantification of collateral status in middle cerebral artery occlu-
sion by measuring the flow in the anterior cerebral arteries (19). 
This allows for close observation of this critical patient group.
Sonography has the ability to verify vessel wall changes in 
cervical arteries including dissection, plaque characterization, 
and detection of unstable thrombi; however, the clinical impli-
cations of especially plaque characterization remain uncertain. 
Likewise, it is standard practice to use Duplex in the preop-
erative evaluation of carotid stenosis for thrombentaretectomy 
using flow measurements to quantify the degree of a stenosis 
even if CTA has documented a reduction in vessel lumen (20). 
By using ultrasound contrast media, it is possible to diagnose 
the presence of persistent foramen ovale or a pulmonary fistula 
if contrast media is detected in the intracerebral circulation after 
Valsalva (21).
Further, continuous sonographic input on the acute thrombo-
sis increases the thrombolytic effects of rTPA (22).
MR angiography may be performed without contrast as Time 
of Flight sequences, i.e., arterial TOF, which is more time con-
suming compared to CT angiography as the scan time is several 
minutes just to visualize the intracranial arteries and longer if the 
cervical arteries are also included. The longer the scan time the 
higher the risk of impairing movement artifacts, which are more 
prevalent in MRi in an acute setting in comparison to planned 
examinations (Havsteen et al.).
Contrast-enhanced arterial TOF-sequences improve detec-
tion of pathology in the vessel lumen in comparison to non-
contrast-enhanced TOF sequences. Contrast-enhanced TOF 
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can be augmented to a resolution down to 0.5 mm isovoxel—the 
same level as CTA—when using 3-T MRi, but at the expense of 
prolonged scan time.
Comparative studies show no difference in the sensitivity 
for detection small aneurisms in comparison to CTA, but the 
specificity seems to be lower (23). High resolution MRi (HR-MRi) 
can characterize arteriosclerotic plaques often using contrast-
enhanced series, which is reported to give prognostic informa-
tion about the risk of subsequent vascular events. HR-MRi can 
also verify dissection changes in small intracranial arteries and 
visualize reperfusion of such vessels. Vessel wall imaging may be 
improved by using higher field strength, i.e., 7T MRI (24).
CT-perfusion can be added to the imaging protocol at the 
price of 5  min more scan-time and an extra 3–5  ms radiation 
dose. Whole-brain CT-perfusion, i.e., 16 cm coverage has been 
introduced and has the ability to show areas with low perfusion 
anywhere in the brain and not restricted to a 4–8 cm slab. This can 
be useful to both quantify the area with perfusion below which 
brain parenchyma is lost, i.e., infarct core as well as surround-
ing salvageable areas with less degree of decreased perfusion, 
i.e., penumbra. Recently, results from the DAWN study (25) 
were presented at the ESOC 2017 conference indicating that 
CT-perfusion—or MR-DWI—can be used to select patients for 
thrombectomy up to 24 h after ictus, increasing the clinical inter-
est in CTP. The DAWN study was set up to address the issue of 
wake up and late presenting strokes and neurointervention based 
on CT-perfusion or DWI-FLAIR mismatch: imaging markers 
of salvageable tissue. In order to differentiate between ischemic 
stroke and stroke mimics, perfusion CT may also be helpful and 
thus compensate for the low visibility of acute ischemia in the 
brain parenchyma on non-contrast CT alone (26).
An additional feature of whole brain perfusion is the pos-
sibility to extract a 4-D angiogram from the perfusion image 
data without having to perform an angiography; these images 
show the filling of the intracranial vessels from the early arterial 
to the late venous phase, which adds a dynamic perspective in 
the evaluation of acute ischemia improving the visualization of 
collateral filling (27). The lack of visualization of the vessels of 
the neck using this method alone can hinder the diagnosis of the 
underlying cause of stroke.
MRI perfusion is able to show the same findings as CT-perfusion 
and when it is based on the use of contrast MRI perfusion has 
considerable advantages especially in obtaining absolute meas-
ures of perfusion. It is also possible to apply perfusion sequences 
without the use of contrast, i.e., arterial spin labeling techniques 
ASL. ASL has proven as reliable as contrast-enhanced perfusion 
techniques in detecting areas with reduced perfusion in acute 
brain ischemia (28) and with the more extensive use of 3T MRi 
technology, the resolution has improved. It is reported that add-
ing ASL to a DWI-based TIA protocol increases correct detection 
of ischemic lesions by 5%. This is primarily the case when the 
DWI lesion is very small and, therefore, doubtful but with a 
simultaneous area of hypo perfusion surrounding it clarifying 
the ischemic diagnosis (29).
Perfusion MRI, in combination with DWI, may also guide the 
decision of mechanical thrombectomy in large vessel occlusion 
with unknown time of onset based on the mismatch of the infarct 
core and the surrounding penumbra on CT perfusion (29), but 
is more time-consuming than the approach used in the DAWN 
study.
CoNClUSioN
Combining several image techniques offers several opportunities 
and advantages. Modern ultrasound apparatus thus offers real-
time image fusion so that sonography of the intracranial vessels 
can be performed using an already performed CTA as anatomi-
cal guide. The CTA images can be viewed simultaneously with 
the live images from TCD and thus assist in the evaluation of 
intracranial stenosis. Likewise, it is possible in a modern PACS 
system to co-evaluate all three modalities and thus extract the 
needed information. This can combine information from a MRI 
perfusion investigation with CTA visualization of the vessel 
and Doppler measurements in order to assess the impact of 
the changes. The information of flow direction and speed form 
sonography in combination with perfusion measurements and 
images of the vessel wall can help to explain the extent and loca-
tion of ischemic lesions and help to decide the treatment options. 
In acute stroke, the access to all these modalities help to ensure 
the correct action needed; however, this requires a neuroradiolo-
gist on call in collaboration with specialized stroke neurologists. 
Often in our experience from a tertiary centre, a good strategy is 
to combine a CTA with an MRI of the brain (DWI, FLAIR, GE/
SWI, ASL) to diagnose the cause of stroke and to rule out stroke 
mimics.
aUtHor CoNtriBUtioNS
This editorial was written with equal participation from the 
authors.
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Assessment of ischemic stroke lesions on computed tomography (CT) or MRI using the 
Alberta Stroke Program Early CT Score (ASPECTS) is widely used to guide acute stroke 
treatment. We aimed to review the current evidence on ASPECTS. Originally, the score 
was developed for standardized lesion assessment on non-contrast CT (NCCT). Early 
studies described ASPECTS as a predictor of functional outcome and symptomatic 
intracranial hemorrhage after iv-thrombolysis with a threshold of ≤7 suggested to identify 
patients at high risk. Following studies rather pointed toward a linear relationship between 
ASPECTS and functional outcome. ASPECTS has also been applied to assess perfusion 
CT and diffusion-weighted MRI (DWI). Cerebral blood volume ASPECTS proved to be 
the best predictor of outcome, outperforming NCCT-ASPECTS in some studies. For 
DWI-ASPECTS varying thresholds to identify patients at risk for poor outcome were 
reported. ASPECTS has been used for patient selection in three of the five groundbreak-
ing trials proving efficacy of mechanical thrombectomy published in 2015. ASPECTS 
values predict functional outcome after thrombectomy. Moreover, treatment effect of 
thrombectomy appears to depend on ASPECTS values being smaller or not present in 
low ASPECTS, while patients with ASPECTS 5–10 do clearly benefit from mechanical 
thrombectomy. However, as patients with low ASPECTS values were excluded from 
recent trials data on this subgroup is limited. There are several limitations to ASPECTS 
addressed in a growing number of studies. The score is limited to the anterior circula-
tion, the template is unequally weighed and correlation with lesion volume depends on 
lesion location. Overall ASPECTS is a useful and easily applicable tool for assessment 
of prognosis in acute stroke treatment and to help guide acute treatment decisions 
regardless whether MRI or CT is used. Patients with low ASPECTS values are unlikely 
to achieve good outcome. However, methodological constraints of ASPECTS have to 
be considered, and based on present data, a clear cutoff value to define “low ASPECTS 
values” cannot be given.
Keywords: stroke, acute stroke treatment, computed tomography, magnetic resonance imaging, Alberta Stroke 
Program early CT Score
FiGURe 1 | Number of publications indexed in MedLine for the search 
term “Alberta Stroke Program early CT Score” per year since 2006.
FiGURe 2 | Alberta Stroke Program early Computed Tomography 
Score template on non-contrast CT with 10 regions distributed over 
the MCA territory in ganglionic and supraganglionic levels.
10
Schröder and Thomalla ASPECTS in Acute Stroke Treatment
Frontiers in Neurology | www.frontiersin.org January 2017 | Volume 7 | Article 245
iNTRODUCTiON
The Alberta Stroke Program Early Computed Tomography Score 
(ASPECTS) is widely used in clinical practice to assess the extent 
of early ischemic changes on brain imaging for acute stroke treat-
ment. ASPECTS has been applied to various imaging modalities 
in acute stroke imaging since its introduction in 2000. ASPECTS 
is a 10-point scoring system with anatomical regions distributed 
over the MCA territory (1).
It was designed as a robust imaging measure to predict out-
come in intravenous thrombolysis. ASPECTS has drawn a lot of 
attention due to its use for patient exclusion in the 2015 trials 
demonstrating efficacy of mechanical thrombectomy (2–4).
Due to high efficacy, we will see an increase of mechanical 
thrombectomy over the course of the next years and with it prob-
ably an increasing use of ASPECTS in routine clinical practice, 
as patient stratification is key in this time-dependent treatment. 
There are also a rapidly growing number of scientific studies using 
ASPECTS in stroke research or addressing methodological ques-
tions concerning ASPECTS (please see Figure 1 for an overview 
of the number of studies published per year over the last 10 years). 
This article aims to summarize the current evidence on ASPECTS 
in a topical and selective review and to explain its applications in 
clinical practice and trials.
ORiGiNAL CT SCORe
The ECASS-1 trial first established the relevance of early 
ischemic signs on non-contrast CT scans prior to intravenous 
thrombolysis (5). Von Kummer et  al. showed in 1997 that 
patients with early ischemic changes in over one-third of the 
MCA territory had a lower chance of good outcome after iv-
rtPA (6). However, identification of patients following the 1/3 of 
the MCA territory paradigm proved to be unreliable in clinical 
practice (7).
Given these limitations to the 1/3 rule and the necessity to 
assess early ischemic changes in a reliable way, Barber et al. devel-
oped ASPECTS. The score was intended as a pragmatic, reliable, 
and easily applicable scoring template for early ischemic changes 
on CT (1).
The template consists of 10 anatomically defined regions, 4 
for subcortical structures [caudate (C); lentiform (L); internal 
capsule (IC); insular ribbon (I)] and 6 for cortical structures in 
the MCA territory, labeled M1–M6 (1, 8) (Figure 2).
The MCA territory is assessed on all axial CT cuts in two 
distinct levels, the “ganglionic” and “supraganglionic” level. All 
axial cuts on the level of the caudate head or below are hereby 
allotted to the ganglionic level, all above to the supraganglionic. 
The caudate nucleus is part of both layers, the head belonging 
to the ganglionic, body, and tail to the supraganglionic level (8).
Early ischemic changes on CT were originally defined as 
intraparenchymal hypoattenuation (loss of gray–white matter 
distinction) and focal swelling. For each ASPECTS region that 
presents with early ischemic changes on at least two consecutive 
cuts, the overall score of 10 is reduced by 1. Thus, a score of 0 
would indicate infarction of all 10 regions.
Despite relatively vague definition of the individual regions 
interrater agreement for dichotomized ASPECTS has been 
described as good (1, 9, 10) with some studies reporting moderate 
agreement (11–13).
ASPeCTS AS PReDiCTOR OF STROKe 
OUTCOMe
The original publication proposed a cutoff of ≤7 on the initial 
non-contrast CT (NCCT) as it predicted functional dependence 
in patients who underwent thrombolysis within 3 h from symp-
tom onset (1).
A larger Canadian study of 936 patients treated with iv-throm-
bolysis in 3 h time window between 1999 and 2001 demonstrated 
a near linear inverse relationship between ASPECTS on baseline 
NCCT and functional outcome (14). However, in 2012, González 
et al. reported no significant prediction of MRS >2 after 6 months 
by ASPECTS on initial NCCT performed within 24 h from symp-
tom onset in 649 patients diagnosed with ischemic stroke (15).
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For iv-thrombolysis a modification of treatment effect by 
ASPECTS could not be proven in 3 or 6 h time windows (16, 
17). Still, in the NINDS rtPA Stroke Study higher ASPECTS 
values were associated with a greater benefit from iv treatment 
with rtPA (16).
ASPeCTS AS PReDiCTOR OF 
SYMPTOMATiC iNTRACRANiAL 
HeMORRHAGe AFTeR THROMBOLYSiS
Barber et al. originally described ASPECTS as a significant predic-
tor of symptomatic intracranial hemorrhage after thrombolysis 
within 3 h from symptom onset (1). This could not be reproduced 
based on data from the ECASS-II or NINDS-stroke trials (16, 17).
In 2009, Puetz et al. published a comprehensive review focus-
ing mainly on NCCT-ASPECTS. As isolated cortical swelling can 
occur in penumbra and infarct core, they proposed the removal 
of isolated focal swelling without hypoattenuation from the early 
ischemic changes relevant for scoring (18).
USe OF ASPeCTS wiTH PeRFUSiON-CT 
AND DiFFUSiON-weiGHTeD MRi
There have been numerous publications assessing the applicabil-
ity of ASPECTS to multiparametric CT and MRI. One prominent 
focus has been the evaluation of different CT Perfusion measures 
using ASPECTS.
Parsons et  al. described cerebral blood volume (CBV) 
ASPECTS within 6  h from symptom onset as a more accurate 
predictor of irreversibly damaged tissue when compared with 
NCCT ASPECTS in 2007 (19). Lin et  al. identified a MTT/
CBV ASPECTS mismatch of ≥1 within 6 h as the optimal cutoff 
to identify a volumetric mismatch of ≥20% (20). MTT/CBV 
ASPECTS mismatch within 3  h from symptom onset was also 
highly correlated with volumetric tissue at risk in a 2011 study 
by Sillanpaa et al.; furthermore, CBV ASPECTS within 8 h from 
symptom onset was superior to NCCT ASPECTS in discriminat-
ing patients with favorable outcome (21, 22). In contrast, a large 
study with 824 patients from a Dutch stroke registry could not 
find an additional impact of CBV and MTT ASPECTS compared 
to only NCCT ASPECTS within 9 h from symptom onset when 
analyzed in a multivariate model. In the same study, CBV and 
MTT ASPECTS were significant predictors of poor clinical 
outcome in univariate analysis (23).
Thus, it is unclear whether CTP ASPECTS offers a clear advan-
tage over NCCT ASPECTS, data at the present state are ambigu-
ous. There have been reports of improved interrater reliability on 
CBV ASPECTS within 4.5 and 9 h from stroke onset compared 
to NCCT ASPECTS (13, 24).
ASPECTS has also been used to assess lesion extent on dif-
fusion-weighted MRI (DWI), usually labeled “DWI-ASPECTS.” 
DWI-ASPECTS within 3  h after symptom onset has been 
proven to predict functional outcome (MRS) and mortality after 
3 months in patients undergoing iv-thrombolysis. As a cutoff to 
identify patients at risk for poor outcome DWI-ASPECTS >6 was 
proposed, though specificity was low at 33% (25). Another study 
identified DWI-ASPECTS >5 within 3 h after onset as a cutoff 
to identify patients with good functional outcome 7  days after 
iv-thrombolysis (26). Based on a cohort of patients with imaging 
between 3 and 24 h after onset, Tei et al. proposed a cutoff of DWI-
ASPECTS >7 to predict MRS ≥3 after 3 months in 2011 (27). In 
all three studies, DWI-ASPECTS was an independent predictor 
of functional outcome. Nezu et al. found DWI-ASPECTS to be 
approximately 1 point lower than NCCT-ASPECTS within 3 h 
from symptom onset in 360 patients, who underwent both imag-
ing modalities. In the same study, there was no significant differ-
ence in area under the receiver operating characteristic (ROC) 
curve of DWI- and NCCT-ASPECTS for prediction of MRS 0–2 
at 90 days. Interrater agreement was higher for DWI-ASPECTS 
(28).
Overall due to the higher sensitivity of DWI (29), DWI-
ASPECTS is more sensitive for the detection of early ischemic 
changes than NCCT ASPECTS (30). After endovascular therapy 
within 12  h from symptom onset DWI-ASPECTS had higher 
interrater agreement and according to ROC analysis outper-
formed NCCT ASPECTS in predicting good functional outcome 
at 90 days poststroke (9).
There have been multiple attempts to use ASPECTS as a sur-
rogate marker for DWI lesion volume and a threshold of <4 has 
been proposed to identify patients with DWI volume >100 ml 
(31, 32). We could show that depending on lesion location esti-
mation of DWI lesion volume by DWI-ASPECTS is unreliable 
(see below) (33).
ASPeCTS FOR USe wiTH MeCHANiCAL 
THROMBeCTOMY
Identification of a clearly defined treatable lesion was highlighted 
as a key issue (34, 35) after three endovascular trials published 
in 2013 (36–38) failed to prove a significant additional benefit 
of endovascular stroke treatment over standard iv treatment. As 
the acute stroke setting comes along with restrictions for time 
consuming post processing of CT or MRI data, ASPECTS among 
other techniques has been proposed as a fast and easy method to 
identify patients suitable for endovascular reperfusion treatment.
There have been several studies suggesting an increased ben-
efit of endovascular treatment for patients with higher ASPECTS 
values using various imaging modalities.
In the Penumbra Pivotal Stroke (39) trial not a single patient 
with ASPECTS <5 on the initial CT scan up to 8 h after symptom 
onset achieved a favorable outcome (MRS 0–2 after 3 months), 
good outcome was significantly more frequent in the ASPECTS 
score >7 group when compared to the ASPECTS score ≤7 group 
[50 vs. 15%; RR, 3.3; 95% confidence interval (CI), 1.6–6.8; 
p < 0.0001].
A further analysis of data from trials using the Penumbra 
system including 249 patients again showed an increase in favora-
ble outcome with higher ASPECTS values (40). Symptomatic 
intracranial hemorrhage was more frequent in patients with low 
ASPECTS scores on initial CT scans. Furthermore, patients with 
ASPECTS 0–4 had significantly worse outcome than patients 
with ASPECTS 5–10 and did not benefit from faster treatment, 
FiGURe 3 | Odds ratios for adjusted treatment effect for MRS 0–2 at 
90 days stratified for different Alberta Stroke Program early 
Computed Tomography Score subgroups in the HeRMeS meta-
analysis; there was no significant heterogeneity of effect (p = 0.29); n 
indicates the number of patients analyzed; cOR, common odds ratio. 
Based on data from Goyal et al. (49).
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thus suggesting a cutoff ASPECTS ≤4 to identify patients with 
poor response to intravascular treatment (40).
In a study of 51 patients undergoing aspiration thrombec-
tomy with a median onset to recanalization time of 292 (IQR 
246–357) min, patients with good outcome (MRS 0–2) had 
significantly higher CBV ASPECTS (CBV ASPECTS 8 vs. 6, 
p = 0.0007), CBV ASPECTS >7 was identified as optimal cutoff 
with a positive predictive value of 65% (41). This was repro-
duced by Lum et al. in a collective of 46 patients within 6 h from 
symptom onset (42).
Soize et  al. reported an independent prediction of outcome 
and of symptomatic intracranial hemorrhage by DWI-ASPECTS 
in 59 patients after mechanical thrombectomy (mean time from 
symptom onset to recanalization 296 min) (43). Inoue et al. iden-
tified DWI-ASPECTS ≥5 as the optimal predictor of favorable 
outcome after 90  days following intra-arterial treatment in a 
collective of 210 patients [median time from onset to MRI 105 
(IQR 75–178) min] (44).
In the IMS-III trial (656 subjects randomized), patients with 
ASPECTS 8–10 on initial NCCT up to 3 h after symptom onset 
were almost twice as likely (relative risk, 1.8; 99% CI, 1.4–2.4) to 
achieve a favorable outcome. However, there was no significant 
treatment by ASPECTS interaction (45).
ASPeCTS iN THe LARGe STeNT-TRieveR 
THROMBeCTOMY TRiALS
In 2015, five randomized-controlled trials demonstrated a strong 
positive effect of mechanical thrombectomy using stent-triever 
devices on patient outcome when compared with standard iv 
treatment alone. Most of these trials used NCCT-ASPECTS for 
patient selection based on the experience of the studies cited 
above.
The first new generation thrombectomy trial published, MR 
CLEAN did not use an ASPECTS threshold for patient exclu-
sion. Patients were included up to 6 h after symptom onset. There 
was a consistent additional effect of intra-arterial treatment over 
all ASPECTS ranges analyzed (0–4, 5–7, 8–10). Intra-arterial 
treatment caused no increase of symptomatic intracranial hemor-
rhage in any of the ASPECTS groups compared iv treatment only. 
However, only 30 patients with ASPECTS 0–4 were analyzed and 
only one of those achieved MRS 2 (46, 47).
Based on the findings of Inoue et al. (44), the SWIFT-PRIME 
study used NCCT- or DWI-ASPECTS ≤5 within 6 h after symp-
tom onset as an exclusion threshold. There was no difference 
in outcome between patients with ASPECTS 6–7 and 8–10 (4). 
Investigators in the ESCAPE study also applied an ASPECTS 
threshold of ≤5 up to 12 h after symptom onset to exclude patients. 
Again, there was no heterogeneity of effect between patients with 
ASPECTS 6–7 and 8–10 (2).
The only study to use DWI-ASPECTS and NCCT-ASPECTS 
in a time window up to 8 h after symptom onset was REVASCAT. 
To account for the different sensitivities of DWI and NCCT-
imaging a threshold of <7 was applied to CT and <6 to DWI 
for patient exclusion. The difference of 1 point between DWI- 
and NCCT-ASPECTS was chosen based on earlier findings by 
Nezu et al. (28). There was no significant difference in outcome 
for patients with ASPECTS ≤7 and above (3). In EXTEND-IA, 
patient selection was not based on ASPECTS but on volumetric 
infarct core to perfusion lesion mismatch (48).
A recent meta-analysis performed a central reading of all pre-
treatment scans from the five thrombectomy trials and found a 
clear benefit of thrombectomy in patients with ASPECTS >5 (49). 
Of note, in the pooled data, median ASPECTS was 9 for both the 
treatment (IQR 7–10) and control (IQR 8–10) groups. Treatment 
effect was analyzed for three ASPECTS strata: 0–5, 6–8, and 9–10. 
While there was a strong and consistent treatment effect for both 
ASPECTS 6–8 and 9–10 with an adjusted odds ratio of OR 2.36 
(95% CI 1.68–3.26) and 2.66 (1.61–4.40), no clear benefit was 
observed for 121 patients with ASPECT 0–5 with an OR of 1.24 
(0.62–2.42). Figure 3 illustrates the odds ratios for the different 
ASPECTS subgroups.
MeTHODOLOGiCAL iSSUeS AND 
LiMiTATiONS OF ASPeCTS
Despite its broad application ASPECTS has limitations. First of all, 
the original ASPECTS score is limited to the anterior circulation 
only (1). Second, ASPECTS shows an unequal weighing of brain 
regions, as first described in 2006 by Phan et al. (50). The template 
is based on anatomical structures, and thus, the individual regions 
cover different amounts of brain tissue. Additionally, the exact 
extent of each region or how much damaged tissue is required to 
render a region affected has never been defined (1).
In a study of 496 patients, we could show that correlation of 
ASPECTS with DWI lesion volume varied considerably depend-
ing on lesion location (33). Figure  4 shows the distribution of 
lesion volumes for ASPECTS values >4. Two patients with the 
same ASPECTS score do not necessarily have similar lesion 
volumes. As lesion volume is a strong predictor of functional 
outcome (51–53), the template’s unequal weighing could com-
promise clinical decisions. If decision making is based solely on 
an ASPECTS threshold this might lead to unjustified exclusion 
FiGURe 4 | Distribution of lesion volumes in patients with diffusion-
weighted MRi (Dwi)-Alberta Stroke Program early Computed 
Tomography Score (ASPeCTS) ≥5, these patients were shown to 
benefit from mechanical thrombectomy in the recent HeRMeS 
meta-analysis (49). Lesion volumes varied considerably in patients with the 
same DWI ASPECTS. Based on data from Schröder et al. (33).
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of patients from clinical trials or even treatment when lesion 
location is not considered.
Depending on analyzed sample, treatment, and imaging 
modality applied, various cutoffs to identify patients at risk of poor 
outcome have been suggested (1, 14, 20, 25–27, 47). Furthermore, 
large studies suggested a linear relationship or even no significant 
outcome prediction by ASPECTS at all (14, 15). Thus, recom-
mendation of one single threshold to identify patients with poor 
outcome based on the available data seems hardly justifiable.
Another issue confined to the widely used NCCT ASPECTS is 
the poor sensitivity in the early period after stroke (29).
CONCLUSiON
ASPECTS is a useful and easily applicable tool for standardized 
evaluation of the extent of acute ischemic lesions that may help in 
the assessment of prognosis in acute stroke treatment regardless 
whether MRI or CT is used. Patients with low ASPECTS values 
are unlikely to achieve good outcome. However, based on present 
data, a clear cutoff value to define “low ASPECTS values” cannot 
be given.
A clear advantage of CT perfusion ASPECTS over NCCT 
ASPECTS has not been established, both could be shown to 
predict poor functional outcome as assessed by the MRS after 
90 days. CBV ASPECTS may offer slightly improved interrater 
reliability.
Due to DWI’s high sensitivity, a key issue of DWI-ASPECTS is 
the definition how much lesioned tissue is required for a region to 
be counted as affected. Formal instructions are lacking. This could 
explain at least part of the variance in the proposed cutoff values. 
There are contradicting reports comparing the performances of 
DWI-ASPECTS and NCCT-ASPECTS for outcome prediction. 
Interrater agreement was improved for DWI-ASPECTS com-
pared to NCCT-ASPECTS.
ASPECTS may further helpful in guiding patient selection for 
enrollment in clinical trials as well as for reperfusion treatment. 
For mechanical thrombectomy, a clear benefit over iv treatment 
alone has been proven for patients with NCCT ASPECTS 6–10, 
while for ASPECTS values 0–5 treatment effect is not clear.
However, when applying ASPECTS cutoffs methodological 
limitations have to be considered resulting from the unequal 
weighing of different brain regions by ASPECTS. As a conse-
quence, stroke lesions with the same ASPECTS rating may have 
quite different lesion extent depending on their location. Thus, we 
do not recommend to stick to strict NCCT- or DWI-ASPECTS 
values for exclusion of patients from treatment but rather con-
sider ASPECTS as a helpful of diagnostic tools that should be 
looked at in the broader perspective including other imaging and 
clinical features.
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Movement artifacts compromise image quality and may interfere with interpretation, 
especially in magnetic resonance imaging (MRI) applications with low signal-to-noise 
ratio such as functional MRI or diffusion tensor imaging, and when imaging small lesions. 
High image resolution has high sensitivity to motion artifacts and often prolongs scan 
time that again aggravates movement artifacts. During the scan fast imaging techniques 
and sequences, optimal receiver coils, careful patient positioning, and instruction may 
minimize movement artifacts. Physiological noise sources are motion from respiration, 
flow and pulse coupled to cardiac cycles, from the swallowing reflex and small spon-
taneous head movements. Par example, in resting-state functional MRI spontaneous 
neuronal activity adds 1–2% of signal change, even under optimal conditions signal 
contributions from physiological noise remain a considerable fraction hereof. Movement 
tracking during imaging may allow for prospective correction or postprocessing steps 
separating signal and noise.
Keywords: acute stroke imaging, dynamic magnetic resonance imaging, motion artifacts, noise reduction, motion 
tracking
BACKGROUND
Movement artifacts are an inherent problem to magnetic resonance imaging (MRI) technology 
where low signal and sensitivity to motion are obstacles driving the development of ever faster 
sequences, e.g., gradient echo, and finer detection equipment, e.g., multichannel phased array coils, 
since the very beginning of nuclear magnetic resonance (NMR) imaging (1). A brief history of 
medical imaging may be found in Ref. (2).
why is Movement a Problem?
Movement artifacts in MRI degrade image quality and may lead to misinterpretation especially 
in MRI acquisitions with low signal-to-noise ratios (SNRs), or for small lesion pathology. In MRI 
sequences with robust visual interpretation, simple motion artifacts can be identified as, e.g., 
ghosting or blurring. In dynamic MRI scans, motion artifacts can cause signal changes that may 
severely confound statistical analysis rendering results unreliable (3, 4).
FiGURe 1 | Coronal reconstruction of echo planar images (ePi) in volume without motion (volume 60, left) and volume with motion artifacts (volume 
305, right). The striped appearance of volume 305 arises from the interleaved EPI sequence used. Two movement measures are shown: (A) Euclidian translational 
displacement in millimeter and (B) DVARS (percent mean signal change) as defined in Ref. (5). In this study of children, with liberal chosen movement thresholds, we 
discarded volumes exceeding threshold and marked in red.
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Movement Artifacts interfere with image 
interpretation in Dynamic and Static MRi
Functional MRI (fMRI)
Functional MRI measures subtle changes in local blood oxygena-
tion and flow related to neural activity. Head motion artifacts can 
cause signal changes, Figure 1. In the worst case, motion-related 
signal changes may be correlated with activation of interest 
in task-based fMRI rendering results difficult to interpret or 
in resting-state where motion-related signal changes may be 
confused with correlations between regions when measuring 
functional connectivity (3–6). By carefully mapping isolated head 
movement artifacts, spatial patterns resembling the default mode 
network were found (3). Also movement induced signal changes 
introduce spatiotemporal structured noise that invalidate the 
typical assumptions of independent and identically distributed 
Gaussian noise in the statistical analysis (7).
Diffusion-Weighted Imaging (DWI)
Diffusion-weighted imaging shows directional variation of diffu-
sion restriction in diffusion-weighted images. Movement artifacts 
cause misalignment of data and introduce noise in the images 
rendering results unreliable (8). The main compromise usually 
stands between resolution and acquisition time. DWI has long 
acquisition times with repetition times up to 10 s which increases 
sensitivity to motion artifacts. For detection of focal diffusion 
restriction, one usually uses three orthogonal diffusion direc-
tions only, with usual 1–2 mm axial resolution and acquisition 
times around 2  min. Diffusion tensor imaging (DTI) used for, 
e.g., fiber tracking and determination of white mater integrity 
needs imaging along at least six gradient directions, usually 20–60. 
DTI has longer acquisition times, usually 4–5 min, rendering it 
more susceptible to motion artifacts than 3-gradient direction 
DWI, Figure 2. In DWI, artifacts due to physiological noise are 
usually minor and can be handled by gating (9–11).
Arterial Spin Labeling (ASL)
Arterial spin labeling is a perfusion imaging technique that uses 
endogenous blood water labeled as “paramagnetic tracer” to esti-
mate cerebral blood flow. One labels blood water prior to inflow 
into the imaging region and subtracts labeled images from control 
images to find a measure proportional with cerebral blood flow. 
Bulk motion during free breathing introduces additional blur-
ring. Breath-hold timing and background suppression schemes 
enhance image quality using series of additional saturation and 
inversion pulses (12).
Structural Images
In structural images movement, artifacts are a smaller problem, 
here the strong SNR enables visual acuity to robustly differentiate 
between anatomical structure and artifact. Yet, challenges remain 
especially in areas with high intrinsic motion, e.g., cardiac MRI 
encounters both cardiac pumping and respiration. Head motion 
has been shown to compromise T1-derived volumetric measure-
ments of cortical thickness, where a seeming reduction imitates 
cortical atrophy (13).
FiGURe 2 | (A) Three and (B) 20-gradient direction diffusion-weighted 
imaging (DWI) images of 68 years female with 2 h lasting transient ischemic 
attack symptoms including right hand paresis and slurred speech. In  
(B), note the occipital ring artifact, blurred contours of the right-sided cortical 
diffusion lesion and blurred cortex outline due to motion. Three-gradient 
direction DWI had acquisition time 2 min and 7 s and 20-gradient direction 
DWI had 4 min and 39 s, both were standard vendor protocols.
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Small Lesions
Small lesions, 3 mm or below, are challenging to image with high 
fidelity and to confidently categorize (14, 15), yet evidence grows 
of their clinical importance as, e.g., small stroke suspect lesion 
presence is associated with increased mortality and morbidity 
(16). Intra- and interrater agreement show deviations <5% and 
2 ml for acute ischemic DWI lesions over 15 ml (17). For smaller 
lesions in a combined minor stroke and TIA cohort with mean 
DWI lesion volume 3.4  ml, measurement intra- and interrater 
agreement were very good (ICC 0.96 and 0.94) (18). Still, 3.4 ml 
corresponds to 1.5 cm lesion length using simple cubic calcula-
tion. While these results are excellent, there still is a way to lesions 
around 3 mm, the usual cutoff value for ischemic lesion inclusion 
(19), these would have volumes of 0.027 ml. Only recently, the 
Standards for Reporting Vascular Changes on Neuroimaging 
group has included lesions below 3 mm as potential signs of small 
vessel disease (14). The goal is to image structures with enough 
detail and minimal distortion to achieve proper identification. 
One path is noise reduction.
Higher Field Strengths Yield Higher 
Resolution and Higher Sensitivity to 
Motion Artifacts
There is a general trend toward higher magnetic field strengths 
(1). At 7  T, angiographic MRI studies using susceptibility-
weighted imaging (20) or Time Of Flight (21) achieve resolutions 
similar to CT (about 0.4 mm in-plane) without contrast agents or 
ionizing radiation. The increase in imaging sensitivity at higher 
field strengths comes with an increase in sensitivity to physi-
ological noise and motion, i.e., the proportion of noise increases 
even without increasing resolution. Higher B fields allow higher 
resolution, where even smaller movement artifacts compromise 
image quality. Also high resolution demands long acquisition 
times and motion artifacts worsen with longer acquisition times. 
The problem remains in future.
Aim
This text aims to assess if subject-related movement artifacts in 
MRI are problematic, i.e., interfere with interpretation, to identify 
where this is the case, investigate the magnitude of movement 
artifacts compared with MR signal and other noise sources, and to 
explore strategies to attenuate or circumvent movement artifacts.
This review is rooted in neuroimaging in a clinical context 
but extends into the realm of research, as many clinicians are 
involved in research budding from clinics striving to improve 
current practice. The intended audience is the interested neurolo-
gist in the interface between clinics and neuroscientific research. 
The review’s scope is introductory, to provide a background for 
understanding the underlying causes of motion artifacts and 
strategies for their mitigation. This is a narrative review based on 
a practical approach; a systematic literature review is beyond the 
scope of this text.
THe SiGNAL AND THe NOiSe
Outlining the Problem: Accurate imaging 
at High Resolution
Small objects are most susceptible to motion artifacts. If the 
resolution, voxel size, is near or larger than the imaged objects, 
their contours appear smeared or blurred and the effect is 
called partial volume. Similarly, movement artifacts degrade 
image quality, because some voxels will be moved to another 
part of the object that may have different signal intensity, e.g., 
in the brain a white matter voxel is moved into gray matter or 
cerebrospinal fluid filled cavities as the lateral ventricles. Thus, 
motion artifacts are most prominent at contrast edges (22), i.e., 
the border between the brain and the skull or air-filled sinuses, 
borders between gray and white matter and around the lateral 
ventricles.
In image acquisition, in-plane acceleration schemes (23–25) 
are attractive as they allow decreasing the length of readout trains. 
This greatly reduces distortions allowing shorter echo times and 
higher resolutions to be achieved. However, in this context, 
it is important to note that these acceleration schemes come 
at the price of reduced SNR (25–27) and importantly can lead 
to increased motion sensitivity, in particular if motion occurs 
during the reference/auto-calibrating signal scans. Furthermore, 
accelerated imaging may cause complicated motion artifacts that 
are more difficult to identify. Simultaneous multislice (SMS) 
acquisition schemes (28, 29) allow speeding up echo planar 
imaging (EPI) acquisition with little or no penalty in the SNR 
for moderate acceleration factors. When compared to in-place 
acceleration schemes, SMS is typically considered to increase 
motion sensitivity to a lesser extent; however, it should be noted 
that SMS can also complicate the identification of motion artifacts 
as they will affect several slices simultaneously and may lead to 
reconstruction artifacts.
One may attempt to correct for motion artifacts, i.e., motion-
induced voxel misplacement relative to adjacent structures, 
TABLe 2 | Contributions to rs-fMRi signal change in whole brain gray 
matter at voxel level in 7 T.
Low frequency drift due to scanner instability 3.2%
Thermal noise 2.3%
Spontaneous neuronal activity 1.9%
RETROICORa 0.1%
Cardiac rate 0.1%
Respiration volume per unit time 0.1%
From Ref. (34).
aEight regressors correlated with physiological activity.
TABLe 1 | Spatial resolution.
B (T) Resolution (mm3)
3 T anatomical images 1 × 1 × 1
3 T functional MRI (fMRI) and perfusion contrast 2 × 2 × 2a
7 T anatomical images 0.5 × 0.5 × 0.5
7 T fMRI 1 × 1 × 1a
From Ref. (1).
aSpatial resolution is inferior to anatomical because the small signal changes, only a few 
percent of the available signal. The use of higher resolutions generally reduces both 
image signal-to-noise ratio and contrast-to-noise ratio.
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by retrograde realignment of the acquired image slices. The 
procedure is called six parameter rigid body transformation and 
mitigates motion-related noise (30, 31). One assumes that the 
imaged volume, i.e., the head, is a rigid body and that its move-
ments can be described with six vectors, three translational along 
orthogonal axes, and three rotational. Retrograde calculations 
of translational and rotational movements are based on the 
assumption that motion happens only between volumes. In real-
ity, most sequences use most of the time for either magnetization 
or readout. Also the method does not account for non-linear 
motion effects or movements in previous scans and their effects 
on field inhomogeneity and spin history (32). Motion artifacts, 
here mostly head motion, cause local changes in the magnetic 
field showing for echo planar sequences as warping in the phase 
encoding direction and for spiral acquisition as blur (22). Yet, the 
six-parameter rigid body transformation greatly reduces motion 
effects and is a common preprocessing step in fMRI.
Scaling the Signal and the Noise
Back to Basics—How Are MR Images Made?
When an object is within a strong magnetic field, one may send 
in a radio wave and receive an echo (the MR signal). The echo is 
determined by two physical constants, T1 and T2. Each tissue has 
unique T1 and T2 relaxation curves.
The MRI signal is created by a strong static magnetic field (B0) 
formed by a superconductive coil combined with one or more 
radiofrequency (RF) fields (B1) created through the application 
of RF pulses and several weak magnetic fields generated by gradi-
ent coils.
For anatomic MR signal (echo) localization in voxels, one 
forms a grid with three orthogonal directions: the RF excita-
tion pulse creates a weaker B1 field. A slice-selective gradient 
cuts the B1 field into two-dimensional (2D) slices, and in each 
2D slice magnetic field gradients encode phase and frequency 
forming cubes (voxels) with unique anatomic localization. The 
RF pulse is tuned to the NMR frequency of hydrogen, which is 
determined by the strength of the B0 field and the gyromagnetic 
ratio of hydrogen. When a patient enters the scanner, the mag-
netic moments of protons in the body tend to align with the B0 
field. The RF pulse is applied and forces the magnetic moments 
to precess at their resonant frequency creating the B1 field. This 
precession and its decay after the RF pulse is switched off (the 
echo) are detected by one or more receive coils as the signal. For 
more details, see, e.g., Ref. (2, 33).
Hydrogen (1H) is the most abundant and commonly used. 
19F, 31P, 7L1, 129Xe, 23Na, 13C, and 17O are examples of other 
nuclei that possess the required spin property, and each requires 
its own RF pulse tuned to its frequency.
How Does the MR Signal Relate to Field Strength?
Higher magnetic field strengths improve image SNR and contrast-
to-noise ratio (CNR) yielding higher resolution. Images with 
higher resolution are more sensitive to motion artifacts. Table 1 
shows that higher spatial resolution is achievable at higher field 
strength and that the spatial resolution of fMRI is inferior to the 
anatomical resolution because signal changes are small, only a 
few percent of the available signal (Table 2). All other conditions 
equal, higher spatial resolution requires longer acquisition times. 
Presumably, one could obtain higher resolution in the same or 
shorter time if one increases the SNR/CNR accordingly.
fMRi Signal
The anatomical basis of the fMRI signal are perfusion and oxygen-
ation-related local changes in venous blood [blood oxygenation 
level-dependent (BOLD) signal] in the cortex and pial vessels 
related to local neuronal activity (35, 36). Deoxyhemoglobin is 
paramagnetic and oxyhemoglobin is diamagnetic. The paramag-
netic deoxyhemoglobin causes a focal artifact of signal loss in 
T2*-weighted sequences because it causes a focal inhomogeneity 
in the magnetic field that increases T2* decay. The metabolic 
demand of neural activity increases local perfusion and oxy-
genation, decreasing local deoxyhemoglobin concentration. The 
relative absence of deoxyhemoglobin and its related signal loss 
is seen as BOLD signal increase. For more details, see, e.g., Ref. 
(37). Movement may veil or obliterate these subtle local field 
homogeneity changes.
The changes in BOLD signal amplitude are only a few percent 
of the signal and are too small for visual assessment. They require 
statistical analysis for detection (Table 2). fMRI precision esti-
mation depends not only on image SNR but also on the signal 
stability on repetition of the image acquisition as reflected in the 
temporal SNR (tSNR) (38).
Breaking Down the Noise into its 
Components—Nuisance Modeling
In fMRI signal, variability may stem from four principal 
sources as thermal and scanner noise arising from system insta-
bilities, physiological noise of BOLD origin (spontaneous neural 
activity), and other physiological noise arising from subject 
motion, cardiac cycles, and respiration (34).
Table 2 shows noise sources’ relative contribution to resting-
state fMRI signal changes.
TABLe 3 | Displacement sizes.
Respiratory motion of the diaphragm Several cm
Respiratory motion of the chest wall Several mm
Cardiac motion >1 cm (44)
Head motion 1 mm (32)
Brain pulsation 0.1 mm (45)
TABLe 4 | Common sources of motion artifacts and practical tips.
Motion source Mitigation strategy
Situational 
subject motion
Protocol design matches population  
(e.g., shorter protocols in acute settings)
Patient preparation including management  
of pain, claustrophobia, or other discomfort
Information, scanner familiarization
Comfortable positioning and optimal head  
support by padding
Reminders
Structural magnetic resonance imaging:  
sedation, if clinically indicated
Functional MRI: task pretraining
Physiological Monitoring
Imaging in chosen intervals on respiratory/cardiac function curve
Skip data with motion above predefined threshold
Post hoc motion correction as estimated from data
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Thermal noise is related to the scanning process and has white 
noise characteristics (uniform power spectral density) and origi-
nates from both the brain tissue and from detector electronics. 
It can be reduced using high B-fields and multichannel detector 
array receive coils.
Non-thermal, physiological noise sources generally cause 
signal fluctuations that scale with the absolute signal strength 
(39–41). In fMRI, the noise sources, physiological and non-
physiological, need to be properly characterized and separated 
from the signal (34, 42). Otherwise they limit the improvements in 
detection sensitivity available with high B-fields (27, 43).
Movement-Related Noise and Its Size
Even healthy and cooperative adults show spontaneous head 
movements up to a millimeter (32). Friston and colleagues (32) 
divided movement-related signal components into differences in 
the position of the object in the scanner and differences due to the 
history of the position of the object. Table 3 shows displacement 
sizes for respiratory, cardiac, and head motion.
Respiration and Cardiac Cycles
During normal breathing, the diaphragm moves several cen-
timeters and the chest wall several millimeters. Most imaging 
strategies involve tracking of the respiratory cyclic motion and 
imaging within a chosen interval of the cycle (gating).
Cardiac motion and arterial pulsation have implications for 
imaging, especially for heart and brain studies. Cardiac pump-
ing consists of longitudinal and radial contraction and causes 
displacements measuring over 1 cm in healthy individuals (44). 
Also beat-to-beat variations in blood flow may cause artifacts 
(46). Further reading on motion in cardiovascular imaging can 
be found in Ref. (47).
Brain pulsation cause non-rigid displacements of up to 
0.1 mm in some brain regions (45). Timing the MRI pulse with 
respiratory and cardiac cycles (gating) may be necessary when 
imaging at submillimeter resolutions in research settings.
Other fMRi- and Dwi-Relevant Artifacts
Susceptibility Artifacts at Tissue Boundaries
The EPI sequence used for fMRI and DWI is vulnerable to sus-
ceptibility artifacts. Differences in tissue magnetic susceptibility 
cause field inhomogeneity at tissue boundaries, which cause spins 
to dephase faster and frequency shifts that produce low signal 
areas. Bone and air have much lower magnetic susceptibility 
than most soft tissues; thus, the signal loss is most pronounced at 
brain–air or brain–bone interfaces.
HANDLiNG THe NOiSe
To achieve as good and reliable data as possible to draw valid 
conclusions from it is an advantage to know if and when motion 
has occurred and its extent. Ideally, external motion tracking is 
preferable to motion estimation from data itself as motion may 
compromise the acquired data. The effective tracking system aims 
to provide real-time tracking with subpixel accuracy and must 
not introduce extra artifacts (48).
General Strategies to Avoid or Reduce 
Physiologic Noise—Quick and Snug
The use of fast imaging sequences and optimal receive coils 
minimizes acquisition times and hence subject motion. One may 
consider using shorter protocols with for restless patient groups. 
Usually these protocols have a compromise between resolution 
and acquisition time, they are useful in, e.g., acute settings where 
quick information without detail is better than no information. 
Careful considerations on comfortable positioning of patients 
in the scanner, instruction and reminding of the importance of 
staying still during the scan are essential. Sedation or anesthesia 
may be necessary for difficult cases. Table 4 summarizes common 
sources of motion artifacts and practical tips.
Shielding
Motion artifacts occur in the phase direction. Saturation bands 
are areas where RF pulses are used to suppress MR signal from 
moving tissues outside the structure one wants to image, e.g., if 
on axial spine images the phase direction is anterior–posterior, 
the saturation band is placed to cover the throat and esophagus to 
avoid motion artifacts from swallowing on the spine.
Alternative Acquisition Patterns in k-Space
Motion artifacts on sequences with simple linear data acquisi-
tion in k-space result in concentrated motion artifacts in certain 
areas of the scan according to the time of the motion event, e.g., 
a single slice becomes unreadable. Alternative, e.g., propeller-
shaped data acquisition patterns fill the center of the k-space 
repeatedly and thereby enabling motion correction between the 
propeller blades if inconsistencies occur (49, 50).
Handling Noise from Respiration and 
Cardiac Cycles in Advanced Neuroimaging
In functional MRI, changes in respiration rate and depth over 
time cause non-neuronal BOLD signal changes, i.e., the varying 
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TR due to, e.g., breath hold will cause T1 effects in BOLD imag-
ing that are difficult to handle. The most common approach in 
neuroimaging is a combination of careful instruction, respiration 
monitoring, skip-and-redo, and post hoc modeling to eliminate 
respiration-induced signal changes (51). Other specific strategies 
to handle artifacts from respiration are respiratory gating or trig-
gering, respiratory compensation or phase re-ordering (52) and 
navigator echoes (53).
Cardiac cycles may be tracked either centrally with ECG 
nodes or peripherally with pulse oximeters. While traveling in 
the arteries, the pulse cycle is delayed and deformed with distance 
to the heart, so the tracking position depends on what one wants 
to image: imaging the heart will yield the best results by tracking 
the cardiac motion. Imaging the brain one can use peripheral 
tracking as the distance between heart and a fingertip is similar 
to the distance between heart and brain.
Noise from respiratory and cardiac cycles may be removed by 
regression using the recorded data in a tape-and-filter strategy 
(7, 51, 54). An alternative strategy is noise removal as estimated 
from the data itself (6, 55, 56).
Head Motion
Head motion can be mitigated through careful instruction and 
comfortable fixating strategies as cushions and straps. Several 
tracking systems to monitor head motion have been developed 
and are described below. The main challenge is real-time integra-
tion of motion-tracking data and image acquisition.
The Case for Prospective versus Retrospective Head 
Motion Correction
Retrospective and intra-image methods for head motion registra-
tion perform image acquisition and head position registration in 
the same data set. Attempts at motion correction within the data 
cannot correct for through-plane motion (57), and also cannot 
account for movements in previous scans with effects on field 
inhomogeneity and spin history (32). The method may introduce 
blurring artifacts through interpolation.
The solution is image acquisition with simultaneous pros-
pective motion correction (57–60). Thesen and colleagues (58) 
deve loped Prospective Acquisition CorrEction (PACE) that 
acquired images for a volume while monitoring the head position 
and realigned the 3D grid to the head position before scanning 
the next volume in a stepwise process with high precision. The 
main disadvantage is that movements are not corrected until they 
are detected in the image, so rigid body transformation is still 
necessary.
Scanner-External Motion Tracking Strategies
The most common strategy for prospective, slice-by-slice head 
movement registration is to optically monitor a marker attached 
to the patient’s forehead with one or more video cameras and 
synchronize data continuously between scanner-external the 
camera space (where the head is) and the magnet space (where 
BOLD signals are recorded) (59–61). This requires are extra 
hardware (camera and marker setup), line of sight between 
camera and head marker, extra software for position registration 
and regular synchronization with the BOLD signal. In addition, 
the initial setup requires time [ca. 30  min (60)] and may be a 
constraint to the patient flow. If the system requires calibration 
for individual patients this prolongs the in-bore patient time and 
worsens motion artifacts akin to prolonged scan time. On the pro 
side, it is universally applicable to all scanner types and relatively 
cheap.
ReMAiNiNG CHALLeNGeS
Power and colleagues (5) have shown that movement artifacts 
imitating functional connectivity correlations between brain 
regions persist even after on-line scanner motion corrections as 
proposed by Thesen and colleagues (58). Here, motion-induced 
artifacts occurred with movements in the order of a few tenths 
of a millimeter or less. They propose a skip-and-redo strategy of 
motion tracking and removal of acquired volumes with tracked 
movement artifacts over a chosen threshold. tSNR may provide 
a quality measure of functional connectivity data (3). Further 
information on postprocessing strategies for noise removal may 
be found in Ref. (3, 4, 6).
At present, scanner internal and external motion correction 
solutions exist, and their main application is to find the areas 
with excessive motion during the scan, so these data can be 
discarded and reacquired. The remaining problem is to integrate 
data continuously from a motion correction setup during image 
acquisition.
CONCLUSiON
In summary, movement artifacts are a problem in applications 
with low SNR, and they are exacerbated at high resolution and 
long acquisition times. Basic important strategies for motion 
reduction are comfortable patient positioning, instruction, and 
reminding of the importance to keep still during the scan. Fast 
imaging techniques are essential for short acquisition times. 
Common preprocessing techniques include realignment and six 
parameter rigid body transformation, and measures to detect 
motion, e.g., DVARS (percent mean signal change). Regression 
of physiological noise from cardiac and respiratory motion is 
recommended employing a nuisance modeling strategy, alterna-
tively, if former is futile, as estimated from the data itself. External 
motion tracking yields best control of motion artifacts that may 
compromise data but requires extra equipment and setup. Its 
main challenge is real-time data integration. Prospective tracking 
of cardiac and respiratory cycles and head motion provide pos-
sibilities for motion correction. Head motion artifacts are ideally 
handled by correction using tracked parameters, or combined 
with a skip-and-redo strategy for movements over a chosen 
threshold.
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About 25% of all strokes occur during sleep, i.e., without knowledge of exact time of
symptom onset. According to licensing criteria, this large group of patients is excluded
from treatment with received tissue-plasminogen activator, the only specific stroke treat-
ment proven effective in large randomized trials. This paper reviews clinical and imaging
characteristics of wake-up stroke and gives an update on treatment options for these
patients. From clinical and imaging studies, there is evidence suggesting that many wake-
up strokes occur close to awakening and thus, patients might be within the approved
time-window of thrombolysis when presenting to the emergency department. Several
imaging approaches are suggested to identify wake-up stroke patients likely to benefit
from thrombolysis, including non-contrast CT, CT-perfusion, penumbral MRI, and the recent
concept of diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR). A
number of small case series and observational studies report results of thrombolysis in
wake-up stroke, and no safety concerns have occurred, while conclusions on efficacy can-
not be drawn from these studies. To this end, there are ongoing clinical trials enrolling
wake-up stroke patients based on imaging findings, i.e., the DWI-FLAIR-mismatch (WAKE-
UP) or penumbral imaging (EXTEND). The results of these trials will provide evidence to
guide thrombolysis in wake-up stroke and thus, expand treatment options for this large
group of stroke patients.
Keywords: wake-up stroke, acute ischemic stroke, thrombolysis, computed tomography, magnetic resonance
imaging, fluid attenuated reversion recovery, DWI-FLAIR-mismatch
METHODS
The literature used in this review was searched in PUBMED and
MEDLINE (1977–2013 October) using the following key words
“wake-up stroke,” “stroke on awakening,” “stroke of unknown
symptom onset,” “thrombolysis,” “diffusion weighted imaging,”
and “fluid attenuated inversion recovery (FLAIR).” The selection
was made by the authors evaluating clinical relevance, currentness,
and methodical correctness. Our purpose was not to give a general
overview of the current state of literature concerning thromboly-
sis in wake-up stroke in general, but to emphasize the possibilities
of treatment for wake-up stroke on the basis of current literature.
Therefore, we have done no systematic literature review but one
focused on our demand.
STROKE AND STROKE THROMBOLYSIS
Patients waking-up with symptoms of stroke represent a specific
subgroup of stroke patients. In general, stroke is the second most
common single cause of death and the most frequent cause of
permanent disability in industrialized countries. Based on WHO
estimates about 15 million people suffer from stroke each year of
whom five million are left permanently disabled (1). As a conse-
quence, stroke carries an enormous social and economic burden
both for the individual patients as for society at large. In the EU
stroke accounts for just over 500,000 deaths each year with just
around 1 in 10 men (9%) and 1 in 8 women (12%) dying from
stroke (2).
The demonstration of efficacy and safety of treatment with
intravenous tissue plasminogen activator (IV-tPA) (3) has ended
an age of therapeutic nihilism and revolutionized stroke care.
Together with the establishment of the stroke-unit concept, throm-
bolysis has motivated the implementation of specialized acute
stroke treatment in most developed countries.
In ischemic stroke, the acute occlusion of a brain vessel leads
to hypoperfusion of the downstream brain areas resulting in an
insufficient supply with oxygen. Within seconds the functional
metabolism of brain cells breaks down, and depending on the
degree and duration of ischemia, the affected brain areas decay.
Thrombolysis aims to reperfuse the brain vessel occlusion by dis-
solution of the clot. In acute stroke, thrombolysis was proven
effective in two randomized controlled trials resulting in a marked
increase of the number of patients with a favorable outcome after
stroke (3, 4). In large observational trials, this effect was repro-
duced in the clinical practice (5), and thrombolysis has become
a keystone of acute stroke treatment. However, thrombolysis was
only proven effective in patients treated within 4.5 h of symptom
onset, and is only recommended for patients to be treated within
this time-window.
WAKE-UP STROKE
In a large number of stroke patients, the time point of symp-
tom onset is not known. About 20–25% of stroke patients realize
stroke symptoms after waking-up from sleep (6–9) (Table 1).
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This subgroup of stroke patients (“wake-up strokes”) differs from
stroke patients who suffer from stroke while being awake and pose
a specific challenge to stroke physicians. The most relevant dif-
ference between both groups is the fact that in wake-up stroke
patients, the exact time point of symptom onset is unknown. As a
result, according to approval criteria and guideline recommenda-
tions, this large group of patients is excluded from thrombolysis
(9, 10), thus excluding patients from the only approved specific
treatment of acute stroke with proven safety and efficacy.
Within the past years, however, wake-up stroke has come into
focus of research activities. Observational studies have brought
insights into clinical and imaging characteristics of wake-up
stroke; new approaches to guide treatment in wake-up stroke
patients have been suggested. Finally, clinical trials are under-
way testing intravenous thrombolysis in patients with unknown
time of symptom onset including wake-up stroke. We will give
an update of the recent insights on wake-up stroke and ongoing
developments that are likely to improve the treatment of these
patients in the near future.
CLINICAL AND IMAGING CHARACTERISTICS OF WAKE-UP
STROKE
There are observations that point toward strokes during sleep
being more severe (15) and having a worse clinical outcome
(12). In a recent large analysis of wake-up-stroke as compared
to stroke while awake, a smaller initial severity for wake-up-stroke
with deterioration to comparable mortality and morbidity was
shown (14). Especially, the secondary deterioration underlines
the potential responsiveness of wake-up stroke for therapy. In
addition, further clinical and imaging observations suggest that
in a large number of patients waking-up with stroke symptoms
strokes may have occurred in the early morning hours so that they
might still be eligible for thrombolysis. There are studies report-
ing comparable frequency of early ischemic signs on CT (EICs)
in wake-up stroke patients as compared to patients studied by CT
within 3 (16) or 6 h of symptom recognition (17). Additionally,
the equal developmental time pattern of EICs in patients with
known and unknown onset in a follow-up from 3 h after recog-
nizing the symptoms to 3 months supports the presumption that
wake-up strokes occur close to awakening (18). An MRI-based
study reported a similar proportion of wake-up stroke patients
showing a perfusion–diffusion-mismatch as compared to patients
within 3 h of symptom onset (11). A similar observation was made
for the detection of “tissue at risk” by perfusion CT in wake-up
stroke patients (18). Together these findings suggest that a large
number of patients with wake-up stroke might still be within a
time-window for thrombolysis when reaching the hospital.
IMAGING APPROACHES TO GUIDE TREATMENT IN WAKE-UP
STROKE
To identify wake-up stroke patients who may benefit from throm-
bolysis two imaging approaches are set in the focus of investi-
gation. The detection of tissue at risk by penumbral imaging
(perfusion–diffusion mismatch, Figure 1), and the approach of
identifying stroke patients within the 4.5 h-time-window by tis-
sue characteristics in stroke MRI [diffusion weighted imaging
(DWI)-FLAIR-mismatch]. Penumbral imaging based on DWI and
Table 1 | Incidence of wake-up stroke.
Wake-up strokes (%) Total Reference
100 (27) 364 (11)
301 (24) 1.248 (8)
349 (14) 2.585 (12)
48 (18) 263 (13)
273 (14)a (+12% “no estimation of onset”) 1.854 (6)
5.152 (30) 17.398 (14)
aOf note, according to clinical in- and exclusion criteria 36% of these patients
were potentially eligible for thrombolysis according to the authors.
FIGURE 1 | MRI perfusion–diffusion mismatch. The small lesion on
diffusion weighted imaging (DWI) represents the infarct core, while the
much larger area in the time to peak map calculated from perfusion imaging
(PWI) identifies the area of critically hypoperfused tissued. The mismatch
between both volumes represents the tissue at risk of infraction and thus,
the target tissue for reperfusion treatment.
perfusion MRI allows to determine the status of damaged tis-
sue in acute ischemia and to distinguish irreversibly damaged
one from critically hypoperfused but potentially salvageable tis-
sue. The mismatch of these was suggested to identify tissue that
is tPA-responsive beyond time-window or independent from time
(19–21). In observational studies, it was shown that tissue at risk
may be saved by reperfusion up to 6 h after symptom onset (22).
Secondary analysis of randomized controlled trials with selec-
tion by penumbral imaging (23, 24) demonstrated a reduction of
final infarct volume (25) and a clinical benefit of thrombolysis in
patients with a large perfusion–diffusion mismatch with an odds
ratio for good clinical response of 2.83 between desmoteplase and
placebo (26). Moreover, large DWI lesion volumes were found to
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be associated with a higher risk of symptomatic intracranial hem-
orrhage (SICH) and poor outcome (22, 27, 28). Thus, the exclusion
of patients with very large DWI lesion volumes by MRI will likely
increase the safety of MRI-based thrombolysis. The re-analysis of
EPITHET and DEFUSE resulted in a more restrictive definition
of the perfusion lesion (29, 30), which are used in the ongoing
Extending the time for Thrombolysis in Emergency Neurological
Deficits (EXTEND) trial (31). The detection of treatable wake-up
strokes by perfusion–diffusion mismatch has been suggested (32–
34) and used in a relatively small non-randomized trial (35). In
line with these considerations, the EXTEND trial will allow the
randomization of patients with wake-up stroke based penumbral
imaging.
The DWI-FLAIR-mismatch (Figure 2) concept refers to the
time-window. There is a broad and striking evidence for the ben-
efit of intravenous thrombolysis of ischemic stroke within 4.5 h
(3, 4, 35). Therefore, it was suggested to use brain imaging to
determine stroke age in the case of unknown symptom onset. The
chronological evolution of ischemic stroke can be characterized
by MRI. A lack of cerebral blood flow with a decreased intracel-
lular energy metabolism causes cytotoxic edema, which can be
detected by a reduced apparent diffusion coefficient (ADC) on
DWI within minutes of stroke (36, 37). During the following 1–4 h,
tissue osmolality increases, accompanied by a net increase of water
(38, 39). This absolute increase of water content can be detected by
T2-weighted MRI (36, 40). Thus, DWI allows an instant determi-
nation of acute ischemic lesions, but gives no evidence of further
developmental changes, which may be characterized by T2. Due
to artificial limitations of T2 caused by the high signal intensity of
cerebrospinal fluid (CSF) with partial volume effects FLAIR is con-
sidered superior and more widely used (41, 42). The pattern of a
visible ischemic lesion on DWI together with normal T2-weighted
imaging or FLAIR is a typical finding in human stroke if imaging is
performed within the first hours of stroke (43–45). These results
are also well in line with data from experimental stroke, where
T2wI failed to detect acute ischemia until about 2–3 h of stroke
(37, 46, 47).
The DWI/FLAIR-mismatch was established (48) to estimate
lesion age and identify patients likely to benefit from thrombol-
ysis. It differs from the perfusion–diffusion coefficient by reveal-
ing information about the time and not the quality of damage.
Single-center studies reported of a 100% visibility of ischemic
lesions after 3–6 h (49–51), and the DWI-FLAIR-mismatch was
shown to identify patients within 3–4.5 h with high specificity
and positive predicted value (PPV) (48–51). These results have
been confirmed in large multicenter studies (PRE-FLAIR: PRE-
dictive value of FLAIR and DWI for the identification of acute
ischemic stroke patients ≤3 and ≤4.5 h of symptom onset – a
multicenter study including 643 patients) (52). The specificity of
the DWI-FLAIR-mismatch to identify patients within the time
frame of 4.5 h was in this study 0.81 and the PPV 0.87. The iden-
tification within 6 h showed a PPV of 0.95 in PRE-FLAIR (50),
and 1 of 0.97 in a Japanese study (49). Concerning the Cochrane
analysis indicating a possible beneficial effect of thrombolysis in
addition with the absence of an increased risk of SICH up to
6 h of symptom onset (53, 54), these results are of paramount
interest for treatment indication. Just recently, an observational
study reported of a high frequency (44%) of wake-up strokes
FIGURE 2 | DWI-FLAIR-mismatch. The upper row gives two examples of a
clearly visible acute ischemic lesion on diffusion weighted imaging (DWI),
while no marked parenchymal hyperintensity is detected on fluid attenuated
inversion recovery (FLAIR) images indicating DWI-FLAIR-mismatch. In the
lower row, a clear hyperintensity can be seen on FLAIR images in the area of
the acute DWI lesion (no DWI-FLAIR-mismatch).
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showing a DWI-FLAIR-mismatch (55). Based on this evidence,
the Efficacy and safety of MRI-based thrombolysis in wake-up stroke:
a randomized, double-blind, placebo-controlled trial (WAKE-UP)
will randomize wake-up stroke patients using the DWI-FLAIR-
mismatch as the imaging criterion to identify patients likely to
benefit from thrombolysis (56).
THROMBOLYSIS IN WAKE-UP STROKE: CASE REPORTS AND
OBSERVATIONAL STUDIES
Resulting from the dissatisfaction with the lack of any evidence-
based treatment recommendations for patients with wake-up
stroke, there is a growing number of case reports and case series,
which report on thrombolysis in patients with wake-up stroke
based on imaging findings (Table 2). These studies used either
plain CT (50), multiparameteric CT (57–60), or multiparamet-
ric stroke MRI (32–35). In a study including 74 patients with
an onset time over 4.5 h and 73 patients with an unknown
onset no difference in eligibility and response for perfusion CT
based thrombolysis was shown (59). Non-contrast CT and clini-
cally indicated thrombolysis for wake-up ischemic stroke in over
80 years old patients was considered to be beneficial concern-
ing the modified Ranking Scale (mRS) after 90 days compared
to non-thrombolysed patients (61), and a comparison with ini-
tial and follow-up examination (mRS) after 90 days of 68 patients
with wake-up ischemic stroke to 326 patients within the time-
window of 4.5 h showed equal results after thrombolysis indicated
by non-contrast CT scan combined with clinical judgment (62).
In a further single-center observational safety study 20 patients
were treated with intravenous thrombolysis in the presence of an
arterial occlusion on CT-A and an ASPECTS score of greater than
five on baseline CT (60).
RESTORE (reperfusion therapy in unclear-onset stroke based
on MRI evaluation) was an observational study in which 83 of
430 patients with an unclear onset of symptoms received tissue-
plasminogen activator (rt-PA), intravenously, intra-arterial, or in
combination. The decision for applying this therapy was made
upon a perfusion–diffusion mismatch of more than 20% and neg-
ative or subtle hyperintensities on FLAIR. The clinical outcome
determined by the mRS after 3 months was in 44.6% favorable and
in 28.9% excellent compared to untreated patients (35). Intracra-
nial hemorrhage with a neurological decline was reported in 6% of
the treated patents. Therefore, a distinct benefit for patients being
treated with rt-PA due to estimation by MRI could be shown.
Restraints of this study are the non-randomized study design, the
non-quantitative measurement of FLAIR, and the relatively small
number of treated patients with unknown symptom onset.
Finally, there is a single-armed observational US American
study of thrombolysis with Alteplase in patients with unknown
symptom onset (MR WITNESS: a Study of Intravenous Throm-
bolysis with Alteplase in MRI-Selected Patients, ClinicalTrials.gov.
Identifier: NCT01282242). MR WITNESS will use the concept of
DWI-FLAIR-mismatch to identify patients likely to respond to
thrombolysis and plans to enroll 80 patients.
In summary, these studies demonstrate the feasibility of imag-
ing guided thrombolysis in wake-up stroke patients while there
was no excess in SICH and outcome appeared in large parts simi-
lar as compared to thrombolysis in patients treated within 4.5 h of
known symptom onset. However, final conclusions to the safety
Table 2 |Trials with thrombolysis with indication set by imaging in wake-up strokes.
Sample size wake-up stroke Imaging method Main results Reference
68 Strokes with unknown onset, all received
IV-tPA (case–control comparison)
NECT Similar outcome as treatment within 4.5 h (mRS
after 3 months, any ICH, symptomatic ICH)
(61, 62)
73 Strokes with unknown onset, in 32 (44%) of
these IV-tPA
Perfusion CT No SICH, 56% good outcome after 3 months
(mRS <2)
(59)
89 Strokes with unknown onset, in 20 (22%) of
these thrombolysis
NECT and CT-A/TCD Two asymptomatic ICH, none symptomatic, two
died of massive infarction, two died of stroke
complications
(60)
80 Wake-up strokes, 46 received thrombolysis
(intra-arterial, IV-tPA, or combined)
NCCT, CT- or
MRI-perfusion–diffusion mismatch
Two symptomatic ICH, better clinical outcome
(mRS) and higher mortality in treated cohort
(57)
43 Strokes with unknown onset, 10 (22%)
received IV-tPA
Perfusion–diffusion mismatch (MRI) One asymptomatic ICH, no symptomatic ICH (32)
32 Strokes with unclear onset Perfusion–diffusion mismatch and
FLAIR(non-quantitative)
No difference in frequency of symptomatic ICH
and 3 months outcome (mRS after 3 months) to
treatment within 4.5 h
(33)
430 Strokes with unknown onset, in 83 (19.3%)
of these thrombolysis (10% IV-tPA only)
Perfusion–diffusion mismatch and
FLAIR(non-quantitative)
Benefit of treatment (after 3 months: 44.6% mRS
0–2; 28.9% mRS 0–1) with safe MRI-based
indication (symptomatic ICH in 6%)
(35)
IV-tPA, intravenous tissue plasminogen activator; NECT, non-enhanced computed tomography; CT-A, CT-angiography; TCD, transcranial Doppler ultrasound; FLAIR,
fluid attenuated reversion recovery; ICH, intracranial hemorrhage.
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and efficacy of thrombolysis in wake-up stroke can only be drawn
from randomized clinical trials.
RANDOMIZED CONTROLLED CLINICAL TRIALS OF
THROMBOLYSIS IN WAKE-UP STROKE
Currently, two randomized controlled trials of intravenous throm-
bolysis allow the enrollment of patients with wake-up stroke:
WAKE-UP and EXTEND.
EXTEND (ClinicalTrials.gov. Identifier: NCT00887328) is
a randomized, multicentre, double-blinded, placebo-controlled
phase III trial of intravenous thrombolysis with rt-PA in ischemic
stroke patients (31). Treatment has to be initiated between 3 h (or
4.5 h depending on local practice) up to 9 h of symptom onset,
or in case of wake-up stroke. For wake-up stroke, the midpoint
between sleep onset (or last known to be normal) and time of
waking-up must not exceed 9 h. Further clinical inclusion crite-
ria include a National Institutes of Health Stroke Scale (NIHSS)
score of 4–26. Patients are studied by MRI including diffusion and
perfusion MRI or CT including CT-perfusion and randomized to
either treatment with placebo or Alteplase (0.6 or 0.9 mg/kg body-
weight based on local practice) if they show a penumbral pattern
on MRI or CT. Penumbral pattern is defined by infarct core volume
<70 ml, perfusion lesion/infarct core mismatch ratio >1.2, and
absolute mismatch >10 ml. For definition of the perfusion lesion
Tmax >6 s for MRI and CT is used, while infarct core is defined
using MRI diffusion imaging or CT-CBF imaging. The primary
outcome measure is a favorable outcome defined by a score of 0–1
on the mRS at day 90. EXTEND aims to enroll 400 patients in Aus-
tralia and in an accompanying study in international study sites
(EXTEND international). There is a European companion study
under preparation (ECASS 4-EXTEND-Europe), which will only
use MRI for patient enrollment.
WAKE-UP (ClinicalTrials.gov. Identifier: NCT01525290) is the
first clinical trial to use the novel approach of DWI-FLAIR-
mismatch to prospectively identify patients for thrombolysis.
WAKE-UP is an investigator-initiated, interventional, random-
ized, double-blind, placebo-controlled, parallel-assignment, inter-
national, multi-center efficacy, and safety study (56). The aim of
WAKE-UP is to test efficacy and safety of MRI-based intravenous
thrombolysis with rt-PA (Alteplase) in patients with unknown
symptom onset, e.g., patients waking-up with stroke symptoms
who otherwise fulfill the approval criteria for intravenous throm-
bolysis in acute stroke. Patients fulfilling clinical inclusion and
exclusion criteria will undergo MRI including DWI and FLAIR.
They will be randomized 1:1 to either treatment or placebo if MRI
is indicative of lesion age of less than 4.5 h, i.e., shows a DWI-
FLAIR-mismatch. Clinical inclusion criteria include age between
18 and 80 years and a disabling neurological deficit. Primary effi-
cacy endpoint is favorable outcome defined by a score of 0–1 on the
mRS 90 days after stroke. Primary safety endpoints are Mortality
and death or dependency 90 days after stroke. WAKE-UP plans to
enroll 800 patients in 40–60 study sites in six European countries
and has started recruitment in October 2012.
CONCLUSION
Patients waking-up with stroke symptoms represent a large group
of stroke patients who are currently excluded from intravenous
thrombolysis based on licensing criteria. Growing evidence from
clinical and imaging studies suggests that a relevant proportion
of patients with wake-up stroke might benefit from reperfusion
treatment and be promising candidates for intravenous thrombol-
ysis. Different imaging approaches have been suggested to select
wake-up stroke patients for thrombolysis, including multipara-
metric CT and MRI. Approaches currently under investigation
involve the identification of tissue at risk of infarction indepen-
dent from time by penumbral imaging and the identification of
patients within the approved time-window for thrombolysis by
the concept of DWI-FLAIR-mismatch. Both approaches are cur-
rently tested in large randomized controlled trials. The results of
these trials are expected to change clinical practice by making avail-
able effective and safe treatment for a large group of acute stroke
patients currently excluded from specific acute treatment.
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MRI is widely used in the assessment of acute ischemic stroke. In particular, it identifies
the mismatch between hypoperfused and the permanently damaged tissue, the PWI-DWI
mismatch volume. It is used to help triage patients into active or supportive treatment path-
ways. COMBAT Stroke is an automated software tool for estimating the mismatch volume
and ratio based on MRI. Herein, we validate the decision made by the software with actual
clinical decision rendered. Furthermore, we evaluate the association between treatment
decisions (both automated and actual) and outcomes. COMBAT Stroke was used to deter-
mine PWI-DWI mismatch volume and ratio in 228 patients from two European multi-center
stroke databases. We performed confusion matrix analysis to summarize the agreement
between the automated selection and the clinical decision. Finally, we evaluated the clini-
cal and imaging outcomes of the patients in the four entries of the confusion matrix (true
positive, true negative, false negative, and false positive). About 186 of 228 patients with
acute stroke underwent thrombolytic treatment, with the remaining 42 receiving support-
ive treatment only. Selection based on radiographic criteria using COMBAT Stroke classified
142 patients as potential candidates for thrombolytic treatment and 86 for supportive treat-
ment; 60% sensitivity and 29% specificity. The patients deemed eligible for thrombolytic
treatment by COMBAT Stroke demonstrated significantly higher rates of compromised
tissue salvage, less neurological deficit, and were more likely to experience thrombus dis-
solving and reestablishment of normal blood flow at 24 h follow-up compared to those who
were treated without substantial PWI-DWI mismatch.These results provide evidence that
COMBAT Stroke, in addition to clinical assessment, may offer an optimal framework for a
fast, efficient, and standardized clinical support tool to select patients for thrombolysis in
acute ischemic stroke.
Keywords: stroke, brain edema, magnetic resonance imaging, brain ischemia, decision-support systems, clinical,
thrombolytic therapy
INTRODUCTION
Neuroimaging is valuable to identify acute ischemic stroke patients
that may benefit from thrombolysis (1, 2). Magnetic resonance
based diffusion- and perfusion-weighted imaging (DWI and PWI)
are widely utilized modalities in clinical practice that aid in
treatment selection (3). While DWI hyper-intense regions typ-
ically indicate cytotoxic edema as a surrogate for permanent
tissue injury, delayed PWI regions correspond to tissue with
compromised hemodynamics (4, 5).
The ischemic penumbra is defined as tissue that is hypoper-
fused to such an extent that focal neurological symptoms arise, but
where neurological function can be restored and tissue survival is
ensured by early reperfusion.
Current PWI techniques are not able to distinguish between
critically hypoperfused tissue and benign oligemia. This short-
coming potentially overestimates the actual mismatch volume and
is especially noticeable with small lesions (6). Additionally, hyper-
intense areas on diffusion-weighted images have shown reversal
following thrombolysis (7, 8). Nevertheless, the PWI-DWI mis-
match is recognized as surrogate for risk at tissue that may be viable
if perfusion is restored timely (4, 9, 10). Accordingly, the volume
of the mismatch and the ratio between the volume of mismatch
and volume of permanent injured tissue (PWI-DWI mismatch
ratio) are two practical markers that are used to help triage stroke
patients into interventional or supportive treatment pathways. For
example, when considered along with other parameters, it has been
shown that patients with a mismatch volume>10 mL and a PWI-
DWI mismatch ratio>1.2 have greater benefit from thrombolysis
compared to those without a significant mismatch (11–13). The
time and expertise required to perform these calculations, along
with inter-observer variability are potential factors that may limit
their utilization and efficacy. To overcome these factors, automated
computer-based algorithms for the determination of PWI-DWI
mismatch have been developed (14). The overall aim of this study
was to compare the agreement and outcomes between a solely
automated computer-based patient triage algorithm and the actual
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clinical decision made for thrombolysis. Herein, we tested whether
the treatment decisions of an automated patient selection software
tool “Computer-Based Decision-Support System for Thromboly-
sis in Stroke” (COMBAT Stroke), were associated with 24 h clinical
and imaging outcomes.
MATERIALS AND METHODS
PATIENTS AND DATA ACQUISITION
Following approval from national and regional ethics commit-
tees, patients with acute ischemic stroke were identified from
the European I-Know consortium (2006–2009) and the Remote
Ischemic Perconditioning Study (RIPS, 2009-2011) (15, 16). Clin-
ical information available in the databases includes gender, age,
time from symptom onset to treatment initiation, immediate and
24 h and 3 month follow-up National Institutes of Health Stroke
Scale (NIHSS) score, lesion laterality, stroke etiology subtype,
treatment (i.e., intravenous recombinant tissue plasminogen acti-
vator (rt-PA), or supportive treatment), admission blood pressure,
presence of intracranial hemorrhage, home medications, platelet
count, and MR angiography-based recanalization status at 24 h.
Only adult patients (age >18) with acute ischemic stroke in the
anterior circulation territory were included. Patients with ischemic
strokes of the vertebrobasilar circulation were excluded.
Standard dynamic susceptibility contrast MRI was performed
on various scanner types at different field strengths (GE Signa
Excite 1.5T, GE Signa Excite 3T, GE Signa HDx 1.5T, GE Signa
Horizon 1.5T, Siemens TrioTim 3T, Siemens Avanto 1.5T, Siemens
Sonata 1.5T, Philips Gyroscan NT 1.5T, Phillips Achieva 1.5T, and
Philips Intera 1.5T). The PWI sequence (TE 30/50 ms for 3 and
1.5 Tesla field strength, TR 1500 ms, FOV 24 cm, matrix 128× 128,
slice thickness 5 mm) was obtained during intravenous injection
of Gadolinium based contrast (0.1 mmol/kg) at a rate of 5 mL/s
followed by 30 mL of physiological saline at the same injection
rate. Echo-planar DWI was obtained at b-value= 0 s/mm2 and
b-value= 1.000 s/mm2. DWI images were automatically linear co-
registered and re-sliced to acute PWI space using SPM8 (Wellcome
Trust Centre for Neuroimaging, UCL, UK).
CLINICAL PRACTICE
Patients form highly specialized stroke centers from Denmark,
Germany, United Kingdom, France, and Spain were included in
this study. The local rt-PA practices follow the general recommen-
dation from American Heart Association, where patients older
than 18 years with no imaging or clinical evidence for hemorrhage
who have significant neurological deficit are eligible for treatment
within 4.5 h of symptom onset. All centers routinely perform DWI
and PWI in clinical practice and use the mismatch information as
well as clinical information in treatment decision-making.
AUTOMATIC MISMATCH ESTIMATION
COMBAT Stroke generates and applies a whole-brain mask to
acute images to exclude non-brain structures, e.g., eyes, cere-
brospinal fluid etc. Next, the software determines the lesion later-
ality by analyzing the acute apparent diffusion coefficient map
(ADC) and the time-to-peak of the tissue curve map (TTP).
The lesion laterality is used to compute a normal tissue refer-
ence and subsequently the algorithm outlines the initially injured
tissue on DWI. Similarly, the algorithm automatically outlines the
hypoperfused lesion on TTP map, and the mismatch is defined as
the part of the hypoperfused lesion that is not contained in the
co-registered DWI lesion. We automatically estimated the PWI-
DWI mismatch ratio and mismatch volume for all patients in the
cohort using COMBAT Stroke.
MANUAL MISMATCH OUTLINING
Comparing automated delineations of the mismatch to those
determined manually by a single expert has the potential to intro-
duce bias, therefore we used four expert raters (neuroradiologists)
with extensive clinical experience in stroke diagnosis. The raters
manually outlined the hypoperfused lesion on TTP maps and the
lesion core on DWI images using in-house developed software.
All raters worked individually and were blinded to each other and
the remainder of the clinical data. Next, an expert rater consensus
mismatch mask was created by summating the ratings (1= lesion;
0= normal) in every image voxel for each of the four expert raters.
We utilized a cutoff summative score of 3 to create the mask to
establish a consensus, consistent with previously described meth-
ods (14). The stroke community has been discussing the optimal
choice of PWI map in stroke management, however no consen-
sus exists. We chose TTP as the PWI modality because of its
perceived superiority in separating normo- and hypoperfused tis-
sue. A recent study demonstrated that TTP performed superior to
deconvolved maps (e.g., MTT and Tmax) in terms of predicting
tissue fate (17).
CONFUSION MATRIX MODELING
Initially, all patients were assessed exclusively on imaging cri-
teria alone: thrombolysis could potentially be administered in
cases were PWI-DWI mismatch ratio >1.2 and mismatch vol-
ume>10 mL. Assessments were made for each patient twice, once
with the use of COMBAT Stroke and again by using the data
generated by the expert neuroradiologists’ consensus. Next, con-
fusion matrices were generated to quantify the performance of (1)
COMBAT Stroke versus actual clinical decision and (2) COMBAT
Stroke versus human measurement. The four entries of the con-
fusion matrix denote true positive (TP, both clinical decision and
COMBAT Stroke agree for thrombolytic therapy), true negative
(TN, both clinical decision and COMBAT Stroke agree for sup-
portive treatment), false positive (FP, COMBAT Stroke supports
thrombolysis, but the patient was treated supportively), and false
negative (FN, COMBAT Stroke advises for supportive treatment,
however the patient was treated with thrombolysis).
Mindful that a multitude of factors are used in the actual clinical
determination of administering thrombolytic treatment, we ana-
lyzed the following presentation variables for the four entries of
the confusion matrix: mismatch volume, NIHSS score, and con-
traindications. The definition of contraindication in this study
was based on the American Heart Association’s Stroke Guidelines
and includes any of the following criteria: systolic blood pres-
sure greater than 185 mmHg, diastolic blood pressure greater than
110 mmHg, evidence of intracranial hemorrhage, use of antico-
agulants, international normalized ratio (INR) greater than 1.7,
and time for symptom onset to treatment greater than 4.5 h, all of
which were available in the database. Subsequently, we analyzed
the clinical outcomes, in terms of mismatch salvage, reduction in
NIHSS score at 24 h, and vessel recanalization determined by MR
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angiography at 24 h, to determine the association between pres-
ence/absence of significant acute mismatch and clinical outcome.
The acute DWI-PWI mismatch was determined as the fraction of
the hypoperfused area, which was not contained in the lesion core
(Figure 1). Infarct evolution at 1 month follow-up was evaluated
on T2 FLAIR for all patients in the cohort. The mismatch salvage
was the portion of the acute mismatch that remained functional at
1 month follow-up. Rank sum-test was conducted to test the dif-
ference in median value of acute decision parameters and clinical
outcomes between the groups.
To examine the relative importance of the presentation vari-
ables (Mismatch volume, NIHSS, and contraindications) in pre-
dicting thrombolytic treatment, we also conducted a classification
and regression tree (CART) analysis. The best spilled of data at
each node was determined by optimization of the Gini’s diversity
index and the analysis was conducted in MATLAB 2010B (The
MathWorks, Inc. Natick, MA, USA).
RESULTS
228 patients (136 males, 92 females) were identified as meeting cri-
teria for analysis from the European I-Know consortium database
and the Remote Ischemic Perconditioning Study. The patient char-
acteristics for the two study populations are shown in Table 1. In
comparison with the I-Know cohort the patients in the RIPS study
had significantly lower neurological deficit at baseline, 24 h, and
3 month follow-up in terms of NIHSS and modified Rankin Score.
No significant difference in the acute mismatch volume between
the I-Know patients [56 mL, 25th and 75th percentile= (5, 133)]
and RIPS patients [36 mL (1, 105)] was observed. 89% of the
patients in the I-Know study were treated actively compared to
100% in the RIPS study. Altogether, 40 patients exceeded the 4.5-h
treatment window, of whom 16 were treated actively. The median
processing time for automatic PWI-DWI mismatch estimation
across all patients was 31 s when processed on an Apple MacBook
Pro, 2.6 GHz Intel Core i7.
CONFUSION MATRIX – COMBAT VERSUS CLINICAL DECISION
186 of 228 patients underwent thrombolytic treatment, with
the remaining 42 patients receiving supportive treatment only
(Figure 2A, columns). Assessment of the cohort based on mis-
match criteria (mismatch> 10 mL and PWI-DWI ratio> 1.2)
alone with COMBAT Stroke classified 142 patients as potential
FIGURE 1 | Schematic illustration of mismatch salvage computation (A,B). The acute lesions are outlined on DWI and TTP (C). Illustrates the concept of
DWI-PWI mismatch (blue region) (D–F). Combining the DWI-PWI mismatch information with the 1-month infarct evolution on T2 FLAIR yields the mismatch
salvage (blue region in F).
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Table 1 | Demographic and clinical characteristics of the patient
cohort.
I-Know RIPS p
Patients 129 99
Male 77 (60%) 59 (60%) 0.108
Median age and IQ range, years 70 (60, 77) 69 (61, 76) 0.922
Left hemisphere stroke 74 (57%) 50 (50%) <0.001
IV t-PA 89 (69%) 99 (100%) <0.001
Median time to treatment and IQ
range, min
188 (150, 280) 164 (137, 220) 0.006
Time to treatment>4.5 H 34 (26%) 6 (6%) <0.001
Treated beyond 4.5 H 10 (29%) 6 (100%) 0.002
Median acute NIHSS and IQ
range
11 (6, 16) 6 (4, 10) <0.001
Median 24 h NIHSS and IQ range 4 (1, 10.25) 2 (1, 6) <0.001
Median 3 months NIHSS and IQ
range
2 (0, 6) 0 (0, 2) <0.001
Median 3 months mRS and IQ
range
2 (0, 3) 1 (0, 3) <0.001
Median systolic BP and IQ range
(mmHg)
145 (130, 158) 150 (140, 165) 0.038
Median diastolic blood pressure 83 (72, 90) 85 (79, 90) 0.406
Anticoagulant therapy 22 (17%) 1 (1%) <0.001
Clopidogrel therapy 18 (14%) 6 (6%) 0.027
Median mismatch volume (mL) 56 (5, 133) 36 (1, 105) 0.179
Mismatch volume <10 mL 37 (29%) 33 (33%) 0.086
Mismatch volume <10 and
>100 mL
51 (39%) 38 (38%) 0.031
Mismatch volume >100 mL 41 (32%) 28 (28%) 0.098
STROKE SUB-TYPES
Cardiac source of emboli 58 36 0.046
Large vessel disease with
significant carotid stenosis
22 16 0.140
Large vessel disease, other 12 10 0.174
Small vessel disease (lacunar) 5 24 <0.001
Carotid dissection 6 2 0.172
Other/unusual cause 3 1 0.315
Undetermined 23 10 0.039
Values represented as median with interquartile ranges presented in brackets.
Sample size, where appropriate, is represented as numbers and the percentage
of the cohort is contained in parentheses.
candidates for thrombolytic treatment and 86 for supportive treat-
ment; 60% sensitivity and 29% specificity, 79% positive predictive
value, and 14% negative predictive value (Figure 2A, rows). The
comparison of COMBAT Stroke with treatment decision based
on manually outlined mismatch statistics demonstrated excel-
lent agreement; 93% sensitivity and 95% specificity, 97% positive
predictive value and 87% negative predictive value (Figure 2B).
VOLUMETRIC AGREEMENT
The correlation between PWI-DWI mismatch volumes using
the automatic algorithm and manual outlines performed by
experts was excellent, with Spearman R= 0.89 [CI: (0.86, 0.91)]
(Figure 3). The mean difference in mismatch volume between the
FIGURE 2 | Confusion matrix analysis (A). The confusion matrix
demonstrates the agreement and disagreement between the clinical
decisions actually rendered (columns) and automated patient selection
based on radiographic criteria alone with the COMBAT Stroke software
(rows) (B). The confusion matrix demonstrates the agreement and
disagreement between manual (columns) and automated (rows)
calculations operating under the principle that thrombolysis should
potentially be administered in cases were PWI-DWI mismatch ratio >1.2
and mismatch volume >10 mL.
manual and automatic approach was 8 mL (SD: 35 mL), indicat-
ing an overall underestimation by COMBAT Stroke (Figure 3).
We observed a significant difference in median mismatch volume
in the manual outlines estimated by COMBAT Stroke between
patients scanned on a 1.5T [median mismatch volume= 80 mL
(27, 135), p< 0.01] versus 3T [median mismatch volume= 29 mL
(1, 95)] MRI. Likewise, this difference was apparent in COMBAT
Stroke estimations; 1.5T: median mismatch volume= 62 mL (13,
106), p< 0.01, 3T: median mismatch volume= 15 mL (0, 102).
ACUTE DECISION PARAMETERS
The patients in the TP group (112 patients actually receiv-
ing thrombolytic treatment where COMBAT stroke determined
them to be potential candidates) had significantly higher median
Frontiers in Neurology | Stroke September 2013 | Volume 4 | Article 140 | 34
Nagenthiraja et al. COMBAT stroke decision-support tool
FIGURE 3 |Volumetric comparisons of mismatch delineations.
On left, x -axis represents the expert consensus mismatch volume and
y -axis represent the mismatch volume estimates by the automatic
approaches. On right, x -axis represents the average mismatch volume
between expert consensus and automatic approaches. The y -axis
represent the difference in mismatch volume between expert
consensus and automatic approaches. The Spearman correlation was
R2 =0.89 [CI: (0.88, 0.91)] for COMBAT Stroke compared with the
manual outlining. The mean difference in volume between manual and
COMBAT Stroke outlining was 8 mL (SD: 35 mL). Solid line indicates
the mean between the two compared methods and dashed lines
indicate mean difference ±2 SD.
mismatch volume [96 mL (48, 144)], compared with TN [12
patients, median= 0 mL (0, 22), p< 0.001], FN [74 patients,
median= 0 mL (0, 3), p< 0.001] and the FP [30 patients,
median= 73.4 mL (28, 109), p= 0.04] (Figure 4A). Addition-
ally, the NIHSS score was significantly higher in the TP group
[median= 11 (7, 16)] compared with TN [median= 6 (4.25,
13.5), p< 0.001], FN [median= 5 (3, 7.5), p< 0.001] and FP
[median= 8 (5, 15), p< 0.001] (Figure 4B). Contraindications
to thrombolysis were present in 83% of the patients in the TN
group and in 73% in the FP group. Among the patients in the
TP and FN groups, contraindications were present in 24 and 23%
of cases, respectively (Figure 4C). A summary of acute decision
parameters statistics and significance levels are given in Table 2 for
TN and FN group.
CLINICAL OUTCOME
The 112 patients in the TP group demonstrated the largest
mismatch salvage [median= 84.8 mL (42, 138)] and signifi-
cantly greater salvage than in the TN [median= 8.2 mL (1, 34),
p< 0.001] and FN groups [median= 1.5 mL (0, 7), p< 0.001].
No significant difference in the volume of salvaged tissue was
observed between the FP group [median= 73.4 mL (44, 109),
p= 0.05] and TP (Figure 4D). The neurological improvement
(assessed by reduction in NIHSS score at 24 h) was significantly
better for the TP group [median= 5 (2, 9)] compared with each
of the other three groups [TN: median= 3 (2, 4), p= 0.03; FN:
median= 1 (−1, 3), p< 0.001; FP: median= 2 (0, 5), p= 0.01]
(Figure 4E). Routine 24 h MR angiography demonstrated recanal-
ization in 42% of the patients in the TP group, 15% of the TN
group, 8% of the FN group, and 10% of the patients in the FP
group (Figure 4F). A summary of 3 month outcomes (mRS and
NIHSS score) are given in Table 2 for TN and FN group.
CART ANALYSIS
According to CART analysis, clinicians based their treatment
decisions on a multitude of factors, but primarily on the pres-
ence/absence of a contraindication (Figure 5). The majority of
the patients who had no contraindications (152 of 228) were
treated with thrombolysis (n= 142). If the patient had one or
more contraindications, the clinician involved the PWI-DWI mis-
match ratio and mismatch volume as a secondary parameter in the
clinical decision-making. Finally, neurological assessment quanti-
fied by NIHSS score appeared to be the least influential parameter
in the regression tree.
DISCUSSION
This study reports a 93% sensitivity and 95% specificity between
automated patient triaging by COMBAT Stroke and treatment
decisions rendered by manually outlined mismatch statistics.
Patients with significant mismatch volume and ratio (TP and FP
groups) at the time of acute MRI imaging demonstrated higher
mismatch salvage compared with those who hadn’t significant
mismatch, regardless the clinical treatment decision (Figure 4).
Not surprisingly, there was a poor agreement between COM-
BAT Stroke and the actual clinical decision made (Figure 2A). This
was most notable in patients that did not receive thrombolysis. In
that group, there were only 12 cases where there was agreement
between clinical and automated decision-making (29% speci-
ficity). In contrast, in 74 cases the clinicians decided to administer
thrombolysis when COMBAT Stroke decided against (60% sensi-
tivity). This poor correlation reflects the many different variables
associated with clinical care and treatment decisions.
Importantly, our results indicate that the patients who did not
meet mismatch treatment criteria based on COMBAT Stroke and
did not receive treatment (TN) had higher rates of recanalization
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FIGURE 4 | Descriptive variables at presentation and follow-up.
Using the confusion matrix established, descriptive variables are
presented related to the mismatch (A,D) and degree of neurological
impairment (B,E). Notably, patients who did not meet radiographic
treatment criteria based on COMBAT Stroke (C) and did not receive
treatment (TN) had equal outcomes (E,F) compared to the patients
who similarly did not meet radiographic treatment criteria, yet received
thrombolysis (FN). Red line=median, box=25th–75th percentiles,
bars image most extreme data points not considered outliers and +
depict outliers plotted individually.
Table 2 | Summary of acute decision parameters and clinical outcome
parameters forTN and FN groups.
TN FN p
Mismatch 0 mL (0, 22) 0 mL (0, 3) 0.26
Mismatch salvage 8.2 mL (1, 34) 1.5 mL (0, 7) 0.06
Acute NIHSS 6 (4.25, 13.5) 5 (3, 7.5) 0.4
∆NIHSS 3 (2, 4) 1 (−1, 3) 0.8
Contraindications 83% 23% N/A
Recanalization 15% 8% N/A
3-Months mRS 2 (1, 3.75) 1 (0, 1.5) <0.01
3-Month NIHSS 2 (0.25, 6.5) 0 (0, 1) <0.01
(15%), larger reduction in NIHSS score (median= 3), and greater
mismatch salvage (median= 8.2 mL) compared to the patients
who similarly did not meet mismatch treatment criteria, yet
received thrombolysis (FN). The analysis of 3 months mRS and
NIHSS score outcomes revealed that patients in FN group had
significantly better functional recovery compared to TN group
(Table 2). It should be emphasized that the patients in FN group
had, in general, the mildest grade of neurological deficit at admis-
sion, Figure 4B. Therefore, selection bias may be a confounding
factor in the good functional recovery observed in this group.
Overall, this data supports a need for greater emphasis on the con-
tribution of strict radiographic criteria in the decision-making
process. Use of an automated software system such as COMBAT
Stroke may provide rapid and accurate information to objectively
contribute to the clinical decision.
In general, the patients COMBAT Stroke identified for potential
treatment and were treated had significantly better neurological
improvement,mismatch salvage,and higher rates of recanalization
compared to the other groups. This indicates the importance of the
size of the mismatch and the ratio of the potentially salvageable
and infarcted tissue with outcome following thrombolysis (18).
Our data suggests that the volumetric assessment of the mismatch
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FIGURE 5 | Decision tree analysis. The CART tree illustrates the classification of patients (PT) into thrombolysis or supportive treatment. The boxes with red
borders indicate a binary question related to the acute clinical or imaging markers. The boxes without red boarders denote patient classification into a treatment
group.
provided by COMBAT Stroke, in conjunction with the clinical
assessment, is potentially a decision-support tool for rapid and
standardized stroke management.
To further investigate the factors that influence decision to per-
form thrombolysis, a CART analysis was performed. About 93%
of patients without contraindications were administered throm-
bolysis (Figure 5). Among the treated patients, 15 and 12% of TP
and FN groups had contraindication to treatment, in contrast to
the 83 and 78% in the TN and FP groups. It could be suggested
that the clinicians in our cohort followed an “aggressive” treat-
ment strategy by administering thrombolysis in the presence of
generally accepted contraindications (19, 20). This is not entirely
unexpected, as each patient’s care must be individualized, and a
risk-benefit ratio of treatment cannot be accurately predicted or
captured from our database variables alone (21).
The main limitations of this study are those inherent in any
retrospective design. We attempted to overcome selection bias by
utilizing a consecutive cohort of ischemic stroke patients from
two detailed multi-center databases. Variations in clinical prac-
tices between, and even within, different hospitals are not pos-
sible to account for and can influence the rates of intervention
and clinical outcome (22, 23). Furthermore, individual aspects of
patient care such as the patient’s own preexisting wishes regarding
treatment are not typically captured in a retrospective analysis.
Unfortunately, the balance between actively and supportively
treated patients was highly skewed, thus drawing conclusions by
comparing the different groups should be done cautiously. The
main technical limitations in this study are the numerous auto-
matic post-processing steps in COMBAT Stroke algorithm. For
instance, the co-registration is fully automated and in cases where
the co-registration is not optimal, the determination of mismatch
volume and mismatch salvage is incorrect. To avoid incorrect esti-
mation of the radiographic parameters, we manually checked all
automated steps in the COMBAT Stroke algorithm.
Our study identifies many aspects of investigating an automated
clinical decision-support tool that can be further investigated in a
prospective fashion. These include any causal effect on neurolog-
ical outcome, radiographic outcome, and even “door-to-needle”
time. The automated process of mismatch volumetric calculation
may also prove valuable in the growing population of patients that
are treated beyond the typical treatment time window based on
dynamic imaging characteristics (24–28).
CONCLUSION
COMBAT Stroke may help to not only identify patients that are
potential candidates for thrombolysis, but also to exclude patients
that are unlikely to experience benefit. COMBAT Stroke, in addi-
tion to clinical assessment, may provide a decision-support tool
for a fast, efficient, and standardized clinical decision-making in
acute ischemic stroke.
www.frontiersin.org September 2013 | Volume 4 | Article 140 | 37
Nagenthiraja et al. COMBAT stroke decision-support tool
ACKNOWLEDGMENTS
The authors wish to thank the Danish National Research Foun-
dation (Leif Østergaard, Kim Mouridsen), The Danish Agency
for Science, Technology and Innovation (Mikkel B. Hansen, Leif
Østergaard, Kim Mouridsen) and the European Commission’s
6th Framework Programme (Contract No. 027294) (Kartheeban
Nagenthiraja, Leif Østergaard) for financial support. We thank Dr.
Irene Mikkelsen, Dr. Niels Hjort, Prof. Grethe Andersen, Dr. Tae-
Hee Cho, Prof. Norbert Nighoghossian, Dr. Susanne Siemonsen
Prof. Jens Fiehler, Dr. Josep Puig Alcantara, Prof. Salva Pedraza, Dr.
Josef Alawneh, and Prof. Jean-Claude Baron for access to patient
data.
REFERENCES
1. Röther J, Schellinger PD, Gass A,
Siebler M, Villringer A, Fiebach
JB, et al. Effect of intravenous
thrombolysis on MRI parame-
ters and functional outcome in
acute stroke <6 hours. Stroke
(2002) 33:2438–45. doi:10.1161/01.
STR.0000030109.12281.23
2. Thomalla G, Schwark C, Sobesky
J, Bluhmki E, Fiebach JB, Fiehler
J, et al. Outcome and sympto-
matic bleeding complications of
intravenous thrombolysis within
6 hours in mri-selected stroke
patients: comparison of a ger-
man multicenter study with the
pooled data of ATLANTIS, ECASS,
and NINDS tPA trials. Stroke
(2006) 37:852–8. doi:10.1161/01.
STR.0000204120.79399.72
3. Neumann-Haefelin T, Wittsack HJ,
Wenserski F, Siebler M, Seitz
RJ, Mödder U, et al. Diffusion-
and perfusion-weighted MRI. The
DWI/PWI mismatch region in acute
stroke. Stroke (1999) 30:1591–7.
doi:10.1161/01.STR.30.8.1591
4. Sorensen AG, Buonanno FS,
Gonzalez RG, Schwamm LH,
Lev MH, Huang-Hellinger FR,
et al. Hyperacute stroke: evalua-
tion with combined multisection
diffusion-weighted and hemody-
namically weighted echo-planar
MR imaging. Radiology (1996)
199:391–401.
5. González RG, Schaefer PW, Buo-
nanno FS, Schwamm LH, Budzik
RF, Rordorf G, et al. Diffusion-
weighted MR imaging: diagnostic
accuracy in patients imaged within
6 hours of stroke symptom onset.
Radiology (1999) 210:155–62.
6. Sobesky J, Zaro WeberO, Lehn-
hardt FG, Hesselmann V, Thiel
A, Dohmen C, et al. Which time-
to-peak threshold best identifies
penumbral flow? A comparison
of perfusion-weighted magnetic
resonance imaging and positron
emission tomography in acute
ischemic stroke. Stroke (2004)
35:2843–7. doi:10.1161/01.STR.
0000147043.29399.f6
7. Fiehler J, Foth M, Kucinski T, Knab
R, von BezoldM, Weiller C, et al.
Severe ADC decreases do not pre-
dict irreversible tissue damage in
humans. Stroke (2002) 33:79–86.
doi:10.1161/hs0102.100884
8. Kidwell CS, Saver JL, Mattiello J,
Starkman S,Vinuela F, Duckwiler G,
et al. Thrombolytic reversal of acute
human cerebral ischemic injury
shown by diffusion/perfusion
magnetic resonance imaging.
Ann Neurol (2000) 47:462–9.
doi:10.1002/1531-8249(200004)47:
4<462::AID-ANA9>3.3.CO;2-P
9. Le BihanD, Breton E, Lallemand
D, Grenier P, Cabanis E, Laval-
Jeantet M. MR imaging of intravoxel
incoherent motions: application to
diffusion and perfusion in neuro-
logic disorders. Radiology (1986)
161:401–7.
10. Warach S, Li W, Ronthal M, Edel-
man RR. Acute cerebral ischemia:
evaluation with dynamic contrast-
enhanced MR imaging and MR
angiography. Radiology (1992)
182:41–7.
11. Nagakane Y, Christensen S, Breken-
feld C, Ma H, Churilov L, Parsons
MW, et al. EPITHET. Stroke
(2011) 42:59–64. doi:10.1161/
STROKEAHA.110.580464
12. Hacke W, Kaste M, Bluhmki E, Broz-
man M, Dávalos A, Guidetti D, et al.
Thrombolysis with alteplase 3 to 4.5
hours after acute ischemic stroke.
N Eng J Med (2008) 359:1317–29.
doi:10.1056/NEJMoa0804656
13. Jauch EC, Saver JL, Adams HP
Jr, Bruno A, Connors JJ, Demaer-
schalk BM, et al. Guidelines for
the early management of patients
with acute ischemic stroke: a guide-
line for healthcare professionals
from the American Heart Associa-
tion/American Stroke Association.
Stroke (2013) 44:870–947. doi:10.
1161/STR.0b013e318284056a
14. Mouridsen K, Nagenthiraja K,
Jónsdóttir KY, Ribe LR, Neu-
mann AB, Hjort N, et al. Acute
stroke: automatic perfusion lesion
outlining using level sets. Radi-
ology (2013). doi:10.1148/radiol.
13121622. [Epub ahead of print].
15. I-KNOW. Integrating Information
from Molecule to Man: Knowledge
Discovery Accelerates Drug Devel-
opment and Personalized Treatment
in Acute Stroke. Aarhus: European
Commision’s Sixth Framework Pro-
gramme (2006).
16. Hougaard KD, Hjort N, Zeidler D,
Sørensen L, Nørgaard A, Thom-
sen RB, et al. Remote ischemic
perconditioning in thrombolysed
stroke patients: randomized study
of activating endogenous neuropro-
tection – design and MRI mea-
surements. Int J Stroke (2013)
8:141–6. doi:10.1111/j.1747-4949.
2012.00786.x
17. Christensen S, Mouridsen K, Wu O,
Hjort N, Karstoft H, Thomalla G, et
al. Comparison of 10 perfusion MRI
parameters in 97 sub-6-hour stroke
patients using voxel-based receiver
operating characteristics analysis.
Stroke (2009) 40:2055–61. doi:10.
1161/STROKEAHA.108.546069
18. Parsons MW, Barber PA, Chalk J,
Darby DG, Rose S, Desmond PM,
et al. Diffusion- and perfusion-
weighted MRI response to throm-
bolysis in stroke. Ann Neurol (2002)
51:28–37. doi:10.1002/ana.10067
19. Barber PA, Zhang J, Demchuk
AM, Hill MD, Buchan AM. Why
are stroke patients excluded from
TPA therapy? An analysis of
patient eligibility. Neurology (2001)
56:1015–20.
20. The National Institute of Neuro-
logical Disorders and Stroke rt-
PA Stroke Study Group. Tissue
plasminogen activator for acute
ischemic stroke. N Eng J Med
(1995) 333:1581–8. doi:10.1056/
NEJM199512143332401
21. Meretoja A, Putaala J, Tatlisumak
T, Atula S, Artto V, Curtze S,
et al. Off-label thrombolysis is
not associated with poor out-
come in patients with stroke.
Stroke (2010) 41:1450–8. doi:10.
1161/STROKEAHA.109.576140
22. Candelise L, Gattinoni M, Bersano
A, Micieli G, Sterzi R, Mora-
bito A, et al. Stroke-unit care for
acute stroke patients: an obser-
vational follow-up study. Lancet
(2007) 369:299–305. doi:10.1016/
S0140-6736(07)60152-4
23. Micieli G, Cavallini A, Quaglini
S. Guideline compliance improves
stroke outcome: a preliminary
study in 4 districts in the Ital-
ian region of Lombardia. Stroke
(2002) 33:1341–7. doi:10.1161/01.
STR.0000013663.27776.DB
24. Fiebach JB, Schellinger PD. MR
mismatch is useful for patient
selection for thrombolysis yes.
Stroke (2009) 40:2906–7. doi:10.
1161/STROKEAHA.109.552877
25. Schellinger PD, Thomalla G, Fiehler
J, Köhrmann M, Molina CA,
Neumann-Haefelin T, et al. MRI-
based and CT-based thrombolytic
therapy in acute stroke within
and beyond established time win-
dows an analysis of 1210 patients.
Stroke (2007) 38:2640–5. doi:10.
1161/STROKEAHA.107.483255
26. Mishra NK, Albers GW, Davis SM,
Donnan GA, Furlan AJ, Hacke
W, et al. Mismatch-based delayed
thrombolysis: a meta-analysis.
Stroke (2010) 41:e25–33. doi:10.
1161/STROKEAHA.109.566869
27. Abou-Chebl A. Endovascular treat-
ment of acute ischemic stroke
may be safely performed with
no time window limit in appro-
priately selected patients. Stroke
(2010) 41:1996–2000. doi:10.1161/
STROKEAHA.110.578997
28. Scalzo F, Hao Q, Alger J, Hu
X, Liebeskind D. Regional pre-
diction of tissue fate in acute
ischemic stroke. Ann Biomed Eng
(2012) 40:2177–87. doi:10.1007/
s10439-012-0591-7
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 24 May 2013; paper pending
published: 19 June 2013; accepted: 07 Sep-
tember 2013; published online: 26 Sep-
tember 2013.
Citation: Nagenthiraja K, Walcott
BP, Hansen MB, Østergaard L and
Mouridsen K (2013) Automated
decision-support system for predic-
tion of treatment responders in acute
ischemic stroke. Front. Neurol. 4:140.
doi: 10.3389/fneur.2013.00140
This article was submitted to Stroke, a
section of the journal Frontiers in Neu-
rology.
Copyright © 2013 Nagenthiraja, Wal-
cott , Hansen, Østergaard and Mourid-
sen. This is an open-access article distrib-
uted under the terms of theCreativeCom-
mons Attribution License (CC BY). The
use, distribution or reproduction in other
forums is permitted, provided the origi-
nal author(s) or licensor are credited and
that the original publication in this jour-
nal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.
Frontiers in Neurology | Stroke September 2013 | Volume 4 | Article 140 | 38
May 2016 | Volume 7 | Article 7739
Review
published: 18 May 2016
doi: 10.3389/fneur.2016.00077
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Anders Fogh Christensen, 
University Hospital of Copenhagen, 
Denmark
Reviewed by: 
Edward Feldmann, 
Brown University, USA  
Vincent Thijs, 
Austin Health Florey Institute of 
Neuroscience, Australia
*Correspondence:
Ricardo C. Nogueira  
rcnogueira28@gmail.com
Specialty section: 
This article was submitted to Stroke, 
a section of the journal 
Frontiers in Neurology
Received: 29 December 2015
Accepted: 02 May 2016
Published: 18 May 2016
Citation: 
Nogueira RC, Bor-Seng-Shu E, 
Saeed NP, Teixeira MJ, Panerai RB 
and Robinson TG (2016) Meta-
analysis of Vascular Imaging Features 
to Predict Outcome Following 
Intravenous rtPA for Acute Ischemic 
Stroke. 
Front. Neurol. 7:77. 
doi: 10.3389/fneur.2016.00077
Meta-analysis of vascular imaging 
Features to Predict Outcome 
Following intravenous rtPA for 
Acute ischemic Stroke
Ricardo C. Nogueira1*, Edson Bor-Seng-Shu2, Nazia P. Saeed3, Manoel J. Teixeira2, 
Ronney B. Panerai3,4 and Thompson G. Robinson3,4
1 Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil, 
2 Department of Neurosurgery, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil, 
3 Department of Cardiovascular Sciences, University of Leicester, Leicester, England, 4 Biomedical Research Unit in 
Cardiovascular Science, Glenfield Hospital, Leicester, England
Background: The present review investigated which findings in vascular imaging 
techniques can be used to predict clinical outcome and the risk of symptomatic intrace-
rebral hemorrhage (sICH) in patients who underwent intravenous thrombolytic treatment.
Methods: Publications were searched, and the inclusion criteria were as follows: (1) 
published manuscripts, (2) patients with acute ischemic stroke managed with intrave-
nous recombinant tissue plasminogen activator (rtPA), and (3) availability of imaging 
assessment to determine vessel patency or the regulation of cerebral blood flow prior 
to, during, and/or after thrombolytic treatment. Clinical outcomes were divided into 
neurological outcome [National Institutes of Health Stroke Scale (NIHSS) within 7 days] 
and functional outcome (modified Rankin score in 2–3 months). sICH was defined as 
rtPA-related intracerebral bleeding associated with any worsening of NIHSS.
Results: Thirty-nine articles were selected. Recanalization was associated with improved 
neurological and functional outcomes (OR = 7.83; 95% CI, 3.71–16.53; p < 0.001 and 
OR = 11.12; 95% CI, 5.85–21.14; p < 0.001, respectively). Both tandem internal carotid 
artery/middle cerebral artery (ICA/MCA) occlusions and isolated ICA occlusion had 
worse functional outcome than isolated MCA occlusion (OR = 0.26, 95% CI, 0.12–0.52; 
p < 0.001 and OR = 0.24, 95% CI, 0.07–0.77; p = 0.016, respectively). Reocclusion was 
associated with neurological deterioration (OR = 6.48, 95% CI, 3.64–11.56; p < 0.001), 
and early recanalization was associated with lower odds of sICH (OR = 0.36, 95% CI, 
0.18–0.70; p = 0.003).
Conclusion: Brain circulation data before, during, and after thrombolysis may be useful 
for predicting the clinical outcome. Cerebral arterial recanalization, presence and site of 
occlusion, and reocclusion are all important in predicting the clinical outcome.
Keywords: ischemic stroke, clinical outcome, intracerebral hemorrhage, cerebral hemodynamics, intracranial 
circulation, cerebral autoregulation, rtPA
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iNTRODUCTiON
A meta-analysis of recombinant tissue plasminogen activator 
(rtPA) trials suggested that there may be a group of patients 
who would benefit from thrombolysis within 6 h of symptom 
onset, if they were carefully selected using advanced imaging 
modalities (1).
There has been an extensive investigation of prognostic 
indices of good outcomes that can be applied before, during, and 
after thrombolysis (2). It is well known that factors, such as age, 
initial National Institutes of Health Stroke Scale (NIHSS) score, 
and systolic blood pressure, are of predictive value for clinical 
outcome and symptomatic intracerebral hemorrhage (sICH) (3). 
Magnetic resonance imaging (MRI), computed tomography (CT), 
and transcranial Doppler (TCD) have also been used as possible 
prognostic determinant tools (4). In particular, arterial occlu-
sion, recanalization, and reocclusion, among other factors, have 
been investigated in terms of outcome prediction (4). However, 
there is a gap in the literature about how many methods, which 
evaluate intracranial circulation, have been used before and after 
thrombolysis to predict the outcome in a systematic fashion, 
together with a critical review of the strengths and weaknesses 
of each method.
The aim of the present review is (1) to undertake a descriptive 
systematic review of studies that have evaluated the intracranial 
circulation before, during, and after thrombolysis; (2) to evaluate 
the parameters that provide prognostic information of clinical 
outcome and/or sICH; and (3) to perform a meta-analysis of 
studies that used such parameters.
MATeRiALS AND MeTHODS
Search Strategy
A literature search strategy, restricted to publications from 
January 1994 to January 2015, was designed to identify cerebral 
hemodynamic studies, which assessed cerebral vessel patency 
and/or autoregulation in acute ischemic stroke patients treated 
with intravenous rtPA. Two reviewers (Ricardo C. Nogueira 
and Nazia P. Saeed) identified studies from PubMed database 
using the keywords “ischemic stroke” AND “rtPA treatment” 
OR “thrombolysis” AND “cerebral hemodynamics” OR “cerebral 
autoregulation” OR “cerebral blood flow control.” Bibliographic 
references of selected articles were examined for additional 
suitable studies. The inclusion criteria were (1) published manu-
scripts in English language, (2) patients (>18 years of age) with 
acute ischemic stroke treated with intravenous rtPA, and (3) 
availability of assessment of intracranial circulation to determine 
vessel patency and/or regulation of cerebral blood flow prior 
to, during, and/or after thrombolytic treatment. The exclusion 
criteria were (1) acute ischemic stroke not managed with intra-
venous rtPA, (2) impossibility to determine the vessel patency or 
the regulation of cerebral blood flow before, during, and/or after 
rtPA administration, (3) non-English language publications, (4) 
non-human models, and (5) case reports. The systematic review 
followed PRISMA guidelines; quality assessment of articles were 
used applying the American Academy of Neurology rating system 
by two raters (Ricardo C. Nogueira and Nazia P. Saeed), reviewed 
by a third investigator (Edson Bor-Seng-Shu) in terms of agree-
ment, and this individual resolved any discrepancies. For the 
meta-analysis, authors of publications with incomplete data were 
contacted for additional information. Moreover, care was taken 
to exclude articles with no comparable data (for example: lack of 
imaging after thrombolysis, lack of clinical outcome measured, 
etc.) and articles with patients included in other articles from the 
same institution to avoid biasing the population sample.
Data extraction
The following data were extracted from each article: sample size, 
presence of a control group, type(s) of diagnostic modality used, 
time delay between assessment and thrombolysis (when stated), 
time interval between rtPA treatment and monitoring examina-
tions (assessment during and following treatment, when stated), 
outcomes, conclusions, and study limitations. The articles were 
grouped according to the method of cerebral hemodynamic 
assessment. Data from cerebral hemodynamic assessment tech-
niques were compared based on their common aspects, primary 
contributions, and limitations.
Outcomes
Clinical outcomes were divided into functional, defined by modi-
fied Rankin scale (mRS) in the late post-thrombolytic therapy 
(2–3 months) with good outcome been considered as mRS ≤2, 
and neurological outcomes, assessed by NIHSS and comprising 
improvement (reduction of 10 points or final NIHSS ≤3) or 
deterioration (increase ≥4 points) in the early post-thrombolytic 
therapy stage (within 7 days). sICH was defined as rtPA-related 
intracerebral bleeding detected by CT or MRI associated with any 
worsening of NIHSS or death. Additional outcome measures were 
arterial recanalization assessed by different scales [thombolysis 
in brain ischemia (TIBI), thrombolysis in myocardial ischemia 
(TIMI), and partial or full recanalization], reocclusion (within 
24 h), and cerebral infarct volume.
Meta-analysis
The variables related to assessment of intracranial circulation were 
identified in each retrieved paper and, if they presented in the 
results a significant correlation with clinical outcome and sICH in 
a multivariate analysis, they were considered for the meta-analysis. 
The software used for meta-analysis was the OpenMetaAnalyst 
(Center for Evidence-based Medicine, Brown University School of 
Public Health – Providence, RI, USA), the binary random-effect 
method was applied, and the heterogeneity of studies was evaluated 
using I2 statistics. To identify for publication bias, a funnel plot and 
Egger’s test were applied in the analysis of any assessed variable, 
where information was available from three or more studies.
ReSULTS
Number of Studies Retrieved
The search in PubMed retrieved 7369 articles. After analyzing the 
title and abstract, a total of 278 articles were deemed suitable. The 
inclusion and exclusion criteria were then applied, leaving 39 arti-
cles for further analysis (Figure 1). Each article was then grouped 
FiGURe 1 | Flow diagram of studies identification.
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according to the neuroimaging technique performed; 26 studies 
used TCD ultrasonography, 2 computed tomography angiography 
(CTA), 10 magnetic resonance imaging angiography (MRA), and 
1 either MRA or CTA. TCD ultrasonography was the most used 
method for cerebral hemodynamic evaluation and was, on average, 
performed on more patients per study, besides presenting the short-
est time interval for follow-up assessment (average 2.4 h).
Characteristics of the included Studies
There were 38 observational studies (37 cohort and 1 case-control) 
and 1 interventional study; no randomized controlled clinical trial 
was identified (please see Supplementary Material). The majority 
of the observational studies (36 of 38) used the neuroimaging 
methods for prognostic purposes, and the remainder used the 
methods for investigating diagnostic accuracy or causation.
After grouping the articles based on the type of cerebral hemo-
dynamic assessment, common findings were as follows.
MR/CT Angiography
Thirteen studies using CTA (2 studies), MRA (10 studies), or 
MRA + CTA (1 study) were included (please see Supplementary 
Material) (5–17). In two studies (one using MRA and another 
CTA), neuroimaging assessment was not performed after rtPA 
treatment. The mean time delay from neuroimaging examination 
to thrombolytic therapy was 40  min, and the mean time for a 
second exam following therapy was 19.2  h. One study had an 
interventional design, and the main outcomes were functional and 
recanalization (TIMI 1–3). rtPA was associated with higher rates 
of recanalization and better functional outcomes. Concerning 
the observational studies, the findings revealed that the presence, 
site of arterial occlusion [proximal middle cerebral artery (MCA), 
distal MCA, or tandem internal carotid artery (ICA)–MCA], and 
the occurrence of partial or full recanalization were related to the 
clinical outcomes and final infarct size. The limitations included 
a small sample size and difficulties in determining the time of 
arterial recanalization.
Transcranial Doppler
Twenty-six studies used TCD as a method for cerebral hemo-
dynamic assessment (please see Supplementary Material) 
(3,  18–42). In 24 studies, cerebral hemodynamic parameters 
were evaluated prior to and after thrombolytic treatment (range 
from 2  h to 2  days), while the remaining 2 studies presented 
only pre-rtPA cerebral hemodynamic data. TCD was the sole 
method for monitoring the cerebral hemodynamic status during 
thrombolysis.
These studies revealed that factors, such as pretreatment TIBI 
classification score, arterial recanalization/reocclusion, and the 
site of occlusion (tandem occlusions, proximal/distal ICA, or 
MCA occlusions), were associated with clinical outcome, infarct 
size, and sICH.
Limitations included the operator-dependence nature of the 
TCD method, the absence of arterial imaging resources (making 
it difficult to determine the site of occlusion), and unfavorable 
cranial windows for ultrasound energy passage.
Pooled Results
The cerebral circulation variables associated with functional and 
neurological outcomes or sICH were arterial recanalization/
reocclusion, presence/absence of arterial occlusion, and the 
site of occlusion (Tables 1 and 2). No article regarding cerebral 
autoregulation (CA) was identified.
For the meta-analysis, 23 out of 39 articles were excluded 
for the following reasons: possibility of overlapping patients 
(12 articles, 964 patients), lack of data able to be compared (6 
articles, 360 patients), and lack of success in obtaining additional 
data (5 articles, 129 patients). Arterial recanalization was sig-
nificantly associated with good functional outcome (OR = 11.12; 
95% CI, 5.85–21.14; p < 0.001) and neurological improvement 
(OR =  7.83; 95% CI, 3.71–16.53; p <  0.001) (Figures  2A,B). 
Both tandem ICA/MCA occlusions and isolated ICA occlusion 
had worse functional outcome than isolated MCA occlusion 
(OR  =  0.26, 95% CI, 0.12–0.52; p  <  0.001 and OR  =  0.24, 
95% CI, 0.07–0.77; p =  0.016, respectively) (Figures  2C1,C2). 
Patients with recanalization followed by reocclusion within 24 h 
of thrombolysis had significant association with neurological 
deterioration (overall OR: 6.48, 95% CI: 3.64–11.56, p < 0.001) 
(Figure 2D). Early recanalization (up to 2 h after thrombolysis) 
was associated with lower odds of sICH (overall OR = 0.36, 95% 
CI, 0.18–0.70; p = 0.003) (Figure 3).
The funnel plots of functional outcomes and sICH were sug-
gestive of potential publication bias, which was confirmed by the 
Egger’s test (intercept: 43.65, p = 0.046; intercept: 1.97, p = 0.003; 
Figures 4A,B, respectively). However, the funnel plot of neuro-
logical improvement did not indicate the publication bias (Egger’s 
test intercept: 1.48, p = 0.83; Figure 4C).
DiSCUSSiON
In 2003, Schellinger et  al. (43) highlighted the importance of 
various diagnostic modalities, such as brain MRI, CT, and TCD 
FiGURe 2 | Meta-analysis of hemodynamic variables related to clinical outcome. (A) Functional outcome (dichotomized mRS) in recanalized versus 
non-recanalized patients. (B) Neurological outcome (NIHSS) in recanalized versus non-recanalized patients. (C) Functional outcome (dichotomized mRS) by site of 
occlusion: (C1) tandem ICA–MCA versus isolated MCA and (C2) isolated ICA versus isolated MCA. (D) Clinical deterioration in recanalization versus reocclusion 
patients. MCA – middle cerebral artery, ICA – internal carotid artery, NIHSS – National Institute of Health Stroke Scale, and mRS – modified Rankin scale.
TABLe 2 | Studies demonstrating association with symptomatic intracerebral hemorrhage.
Article Method variable Outcome Result
Saqqur et al. (36) TCD Persistence of occlusion ≥2 h sICH OR = 6 (1.5–21.3) p = 0.01
Saqqur et al. (36) TCD Recanalization beyond 24 h or persistent occlusion sICH OR = 3 (1.1–10) p = 0.04
Saqqur et al. (36) TCD Persistence of proximal occlusion at 2 h sICH OR = 5 (1.5–15) p = 0.008
Saqqur et al. (36) TCD Persistence of proximal occlusion at 2 h (excluding reocclusion) sICH OR = 8 (3–26) p < 0.001
TABLe 1 | Studies demonstrating association with clinical outcome.
Article Method variable Outcome Result
Molina et al. (19) TCD Early recanalization (6 h) Good outcome (mRS ≤2) in 90 days OR = 23.4 (5.4–96) p = 0.001
Nighoghossian et al. 
(12)
Multiparametric 
MRI
Recanalization NIHSS at day 60 Multiple linear regression 
p = 0.0001
Molina et al. (3) TCD Proximal occlusion before thrombolysis Good outcome (mRS ≤2) in 90 days OR = 0.25 (0.10–0.61) p < 0.001
Sims et al. (17) CTA Absence of occlusion Early improvement (4 points in NIHSS) OR = 5.0 (1.1–23.3) p = 0.04
Sims et al. (17) CTA Absence of occlusion Good outcome (mRS ≤2) in 7 days OR = 6.8 (1.3–34.6) p = 0.02
Saqqur et al. (42) TCD Reocclusion Clinical deterioration (4 points in NIHSS) OR = 4.9 (1.7–13) p = 0.002
Saqqur et al. (41) TCD Distal × proximal MCA occlusion before 
thrombolysis
Good outcome (mRS ≤1) in 90 days OR = 2.1 (1.1–4) p = 0.025
Tsivgoulis et al. (34) TCD Recanalization within 2 h Good outcome (mRS ≤2) in 90 days OR = 5.98 (2.58–13.84) p < 0.001
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ultrasonography, for the decision-making process regarding 
thrombolytic therapy for acute ischemic stroke. Furthermore, 
the assessment of cerebral hemodynamic during and after throm-
bolytic therapy may be important to determine the parameters 
that could influence the clinical outcome, especially in the face 
of new research investigating the aggressive control of ABP in 
this scenario (44). Finally, with the new guidelines regarding 
endovascular treatment (45), the evaluation of cerebral circula-
tion will be useful to determine proximal occlusion and also 
could select patients who were excluded from endovascular 
trials, but could benefit from the interventional therapy. To our 
knowledge, the present paper is the first to use techniques of 
systematic review and meta-analysis to verify the influence of 
assessment of intracranial circulation, provided by brain MRI, 
FiGURe 4 | Funnel plot assessing publication bias: (A) Functional outcome (dichotomized mRS) in recanalized versus non-recanalized patients; 
(B) Symptomatic intracranial hemorrhage in recanalization versus non-recanalization; and (C) Neurological outcome (NiHSS) in recanalized versus 
non-recanalized patients. NIHSS – National Institute of Health Stroke Scale and mRS – modified Rankin scale.
FiGURe 3 | Meta-analysis of the hemodynamic variables recanalization versus non-recanalization related to symptomatic intracerebral hemorrhage.
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CT, and TCD ultrasonography on clinical outcomes and sICH 
in acute ischemic stroke patients who underwent thrombolytic 
therapy (46).
Considering the hemodynamic studies reviewed here, the 
specific details of each study are worth emphasizing. MRA and 
CTA represent valuable options for detecting and confirming 
large vessel occlusion, but cannot identify the timing of reca-
nalization (8, 11, 15, 16, 37, 47–49). Furthermore, early imaging 
changes are the strong predictors of sICH (50) and could be used 
in association with cerebral circulation parameters. The primary 
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limitations of MRA and CTA studies were the time delay in 
assessment after thrombolytic treatment, the use of intravenous 
contrast media, and the difficulties in determining the timing of 
recanalization (6, 9, 12, 48, 49). However, it is well established 
that the presence and timing of brain arterial recanalization 
correlates with clinical outcome, hemorrhagic complications, 
and infarct size (14, 19–22, 25, 29, 31, 36, 37). For this purpose, 
TCD ultrasonography remains a valuable choice, as this method 
exhibits the following advantages: (1) device portability, (2) low 
cost of the method, and (3) real-time monitoring during throm-
bolysis (3, 18, 20–23, 25, 26, 30, 34, 36, 37). TCD ultrasound 
may also play a therapeutic role during thrombolysis; a recent 
systematic review revealing that sonothrombolysis associated 
with rtPA is a safe procedure that increases recanalization rate 
in the acute ischemic stroke setting (51, 52). However, TCD is 
operator-dependent, cannot reliably monitor small brain artery 
occlusion, and does not determine the exact site of occlusion. 
Therefore, in the future, a combination of methods may be 
important.
Only variables that, in the retrieved papers, presented signifi-
cant correlation with outcome (clinical or sICH) in a multivariate 
analysis were included in the present review. The main variables 
associated with clinical outcome or sICH were recanalization, 
reocclusion, and the presence and site of occlusion. Our meta-
analysis showed that recanalization is significantly associated 
with functional and neurological outcomes, but not with sICH. 
In fact, some studies have shown that the time of recanalization 
is associated with neurological recovery (21), and the persistence 
of occlusion is associated to sICH (36). Our findings are in agree-
ment with a previous meta-analysis, which found significant 
association between recanalization and clinical outcome (OR: 
4.43) and no association between recanalization and sICH, but 
comparisons should be made with caution because the previous 
meta-analysis evaluated intravenous, intra-arterial, and mechani-
cal therapies (53).
Most of the conclusions presented in this paper have already 
been presented in endovascular therapy (EVT) trials. However, 
some issues, such as reocclusion, are more suitable for investi-
gation by non-invasive imaging techniques. Furthermore, we 
believe that the information gathered in this paper, reaffirming 
the conclusions obtained with EVT trials and pointing the positive 
and negative aspects of other imaging techniques, is important to 
support the utilization of multimodality imaging in stroke care. 
A multimodality approach may provide a better understanding 
of the natural evolution of this pathology, and perhaps better 
future selection of patients for interventional therapies, who 
are currently excluded. Finally, strengthening the importance of 
different imaging modalities in the intravenous therapy setting is 
important for centers that still do not have access to interventional 
therapy, especially in low-income countries.
There are few studies concerning CA during acute and suba-
cute ischemic stroke. Existing publications on CA in ischemic 
stroke reveal a transient impairment of CA during the subacute 
stages of major ischemic stroke (54–57). Interestingly, using 
animal models, it has been demonstrated that rtPA displays 
neurotoxic properties that can disrupt the blood–brain barrier, 
damage vessels, and possibly impair the CA (58). To our knowl-
edge, only one study of CA after rtPA treatment in humans is 
available, which concluded that this treatment does not contrib-
ute to impaired CA. However, this study evaluated CA 10–20 h 
after rtPA treatment; not eliminating the possibility of an initial 
detrimental effect by rtPA on CA (59).
The limitations of the current review are (1) the search strategy 
was restricted to just one database, although PubMed comprises 
a majority of the relevant articles on this topic; (2) the inclu-
sion criteria were limited to research of standard dose of rtPA 
(0.9 mg/kg) for thrombolysis, although low dose of rtPA (0.6 mg/
kg), other thrombolytic drugs (desmoteplase or tenecteplase), or 
other methods (mechanical thrombectomy, intra-arterial rtPA) 
have been investigated; (3) lack of analysis concerning the effect 
of recanalization time on clinical outcome, although the present 
meta-analysis showed the clinical impact of recanalization at the 
first 24 h; (4) use of different imaging modalities for detecting 
arterial occlusion and recanalization; (5) data heterogeneity 
(especially number of patients included in each study, quality of 
study, and average stroke severity) from different publications; 
and (6) potential publication bias of some outcomes’ measures 
confirmed by the funnel plot and Egger’s test.
CONCLUSiON
In conclusion, the use of brain assessments of cerebral circula-
tion before, during, and after rtPA thrombolysis is promising, 
especially, to predict outcome. Arterial recanalization, presence 
and site of occlusion, and reocclusion relate to clinical outcome. 
Future studies of prognostic accuracy should investigate these 
factors, ideally using more than one method of cerebral hemody-
namic assessment. In addition, the evaluation of cerebral blood 
flow regulation mechanisms during and after rtPA treatment 
should be explored.
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Intracerebral hemorrhage (ICH) is the most feared risk of systemic thrombolysis for ST-elevated
myocardial infarction, pulmonary embolism, or acute ischemic stroke. Clinical, radiological, and
pathological evidence suggests that cerebral small vessel disease and, in particular, cerebral amyloid
angiopathy (CAA) may contribute to or in some cases directly underpin thrombolysis-related
intracerebral hemorrhage (TICH) (1). Further developments, particularly in neuroimaging, have
strengthened this hypothesis, hinting at the prospect of identifying biomarkers tomeasure TICH risk
for individual patient groups. Emerging biomarkers for CAA such as lobar cerebral microbleeds (2)
may become increasingly useful for outcome endpoints in clinical trials and patient risk stratification
for TICH (3).
Thrombolysis-related intracerebral hemorrhage is a complex pathophysiological process. For
ischemic stroke patients, a key issue is the location of TICH, i.e., hemorrhage into the area of ischemia
vs. hemorrhage in a remote non-ischemic site (occurring in about 20% of patients with symptomatic
TICH). Classification of TICH has traditionally focused on clinical and radiological features (4),
with less emphasis on whether different mechanisms might be implicated in TICH in remote from
or within the acute infarcted region (5) or whether pathological assessment has occurred.
Coregistered Pittsburgh compound B positron emission tomography (PiB-PET) imaging has
revealed that spontaneous hemorrhage hotspots preferentially occur at locations with increased
amyloid β-protein burden (6). In patients treated with recombinant tissue plasminogen activator
(rt-PA) for acute ischemic stroke, cerebral amyloid β-protein (as detected with PiB-PET) retention
was higher in patients with parenchymal hemorrhage compared to patients without (7). Although
PiB-PET has somewhat poor spatial resolution and cannot reliably resolve parenchymal and cere-
brovascular amyloid β-protein, the finding is probably one of the strongest pieces of radiological
evidence implicating CAA in TICH. Matrix metalloproteinase 9, a zinc-dependent endopeptidase
and a marker of hemorrhagic transformation after ischemic stroke, is released from neutrophil
granules by rt-PA in humans (8). Amyloid β-protein can also release and activate MMP-9 from
mouse endothelial cells (9), suggesting that convergent risk factors may lead to hemorrhage.
Cerebral microbleeds identified on MRI in a lobar distribution are considered a characteristic
hemorrhagic marker of a vasculopathy related to CAA (2). It has slowly emerged that multiple
microbleeds might increase the risk of symptomatic ICH following thrombolysis treatment, a
relationship which increases with increasing numbers of microbleeds (10, 11). In more recent
studies with larger groups of ischemic stroke patients receiving intravenous thrombolysis in both
European and Chinese populations, multiple cerebral microbleeds were more clearly associated
with symptomatic and parenchymal hemorrhage, respectively (12, 13). Future study may provide
insights into potential mechanisms, and meta-analyses may highlight the relative importance of
lobar and non-lobar cerebral microbleeds in stratifying the intracerebral hemorrhagic risk from
thrombolysis.
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In a review in 2004 (1), we identified 10 patients with patho-
logical investigation of TICH, 7 of whom had evidence of CAA.
All of these patients had been treated for acute myocardial
infarction and nine of the patients had multiple hemorrhages in
a lobar distribution. With an increasing emphasis on primary
percutaneous intervention for ST-elevated myocardial infarc-
tion, it may not be surprising that no further TICH cases fol-
lowing thrombolysis for acute myocardial infarction have been
reported. However, although thrombolysis rates have increased
for acute ischemic stroke patients, in an updated systematic lit-
erature search, only two further autopsy TICH cases (multiple
and both hemispheres) have been reported in the stroke litera-
ture, both of whom had CAA (14). The relative lack of human
pathological studies compared to neuroimaging studies ham-
pers further developments in this area. A pathological register
attached to a clinical register would enhance our understanding
of TICH, particularly in the older population with acute ischemic
stroke.
The known predictors of clinically significant TICH currently
include age, clinical stroke severity, high blood pressure, hyper-
glycemia, early CT ischemic changes, large baseline diffusion
lesion volume, leukoaraiosis, and cerebral microbleeds on MRI;
the evidence for a role of CAA in TICH continues to accumulate.
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Intravenous thrombolytic therapy in acute ischemic stroke patients is complicated by intracerebral
hemorrhage (ICH) at a site remote from the infarcted area in roughly 2–3% of cases (1, 2).
Historically, the etiology underlying these was proposed to be hemorrhagic infarction at a distant
unrecognized silent focus of ischemia frommultiple emboli. However, the use of diffusion-weighted
imaging has demonstrated clear examples of remote intracerebral hemorrhage (rICH) occurring
at sites devoid of ischemia, signifying alternate contributory mechanisms (3). Cerebral microb-
leeds (CMBs) are markers of bleeding-prone microangiopathies – most commonly hypertensive
arteriopathy and cerebral amyloid angiopathy (CAA) (4) – that are visualized on T2*-weighted
magnetic resonance imaging (MRI). Pathological studies have demonstrated intact erythrocytes
underlying 13% of CMBs (5) implying that a subset of these lesions reflect acute or subacute areas of
microhemorrhage. Fittingly, radiographic studies have demonstrated development of new CMBs in
5–13% of acute ischemic stroke patients within the first week after symptom onset (6–8). It is hence
biologically plausible that thrombolysis-induced expansion of rapidly appearing CMBsmight be the
cause underlying a proportion of rICH in acute ischemic stroke patients. In this Opinion piece, we
explored this hypothesis by pooling available evidence from relevantMRI patient cohorts with acute
ischemic stroke.
Two recent studies from east-Asian centers including a total of 345 patients have assessed the risk
of rICH in patients who develop new post-stroke CMBs. Both studies used exclusively intravenous
thrombolysis with rtPA: the dose used was 0.6mg/kg in one study (7) and 0.9mg/kg in the other (8).
Overall, 129 (39%) of the patients had CMBs on pre-treatment baselineMRI and 17 (5%) developed
new CMBs at 24 h post-thrombolysis. Post-thrombolysis rICH occurred in 2% (n= 7) of the entire
population. In fixed effects pooled meta-analysis of the data, patients who developed new CMBs
had a significantly increased risk of rICH than patients without new CMBs (odds ratio (OR) 16.15,
95% CI 3.72–70.18, p< 0.0001; Figure 1). The results were consistent in sensitivity analysis using a
random effects model.
These findings, although preliminary, suggest that thrombolysis-induced expansion of newCMBs
might account for a proportion of rICH in acute ischemic stroke patients. Post-thrombolysis rICH
has been previously documented to occur at a site of CMB (9) and meta-analyses have suggested
elevated risk of any post-thrombolysis symptomatic intracerebral hemorrhage in patientswithCMBs
(10, 11). However, whether these lesions – detected on baseline pre-thrombolysis MRI – were
acute CMBs or simply a chronic marker of underlying hemorrhage-prone microangiopathies in the
brain is uncertain, as thus far only chronic-subacute CMBs have been proposed to possibly have a
distinctive MRI signature (12).
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FIGURE 1 | New cerebral microbleeds and remote (i.e., extra-ischemic) intracerebral hemorrhage. Meta-analysis of the association between symptomatic
remote intracerebral hemorrhage (ICH) risk in patients with acute ischemic stroke treated with intravenous thrombolysis, in relation to the presence of new cerebral
microbleeds (CMBs) on MRI. Moderate heterogeneity was detected across the different studies pooled in the meta-analysis. Two authors search PubMed and
extracted relevant data for the analysis. We quantified the strength of the association between new CMBs and ICH using odds ratios (OR) and their corresponding
95% CIs, with the inverse variance method for weighting. We assessed statistical heterogeneity using I-squared statistics and also visually through inspection of the
forest plot. We repeated all analyses using random effects models. Meta-analyses were performed using Stata 11.2 (StataCorp LP, Texas).
Two cohorts published in the last year have attempted to charac-
terize clinical predictors of rICH (1, 2). In the Safe Implementation
of Treatments in Stroke-International StrokeRegister (SITS-ISTR)
prior stroke and older age were independently associated with
rICH. However, the lack of robust associations with traditional
ischemic risk factors led the authors to postulate whether another
undetected mechanism, including CAA (13), was at play (2).
Conversely, prior transient ischemic attack (TIA) was the only
clinical predictor of rICH in an Australian cohort (1). Although,
this observation could support the notion that rICH occurs from
hemorrhagic transformation of unrecognized acute or subacute
ischemic infarcts, patients with CAA often experience transient
focal neurological episodes that can mimic TIA, and are highly
predictive of future lobar ICH (14).
Together, these observations raise the possibility that multiple
etiologies (both primary hemorrhagic and primary ischemic)
likely contribute to the pathogenesis of post-thrombolysis
rICH. They also demonstrate the rapidly evolving nature of
microbleeds in the acute phase of ischemic stroke, suggesting
a potential role of an active small vessel microangiopathic
process (15). As our pooled analysis is unadjusted, it remains
to be determined whether the association between new CMBs
and rICH is indeed an independent one or rather simply an
indirect association due to common underlying pathophysiology,
such as small vessel disease, stroke-induced acute hypertensive
response, or neurovascular unit dysfunction from up regulation
of inflammatory cascades. Future larger studies that incorporate
a comprehensive assessment of both clinical and MRI predictors
of rICH, as well as circulating markers of inflammation, would
further elucidate this hypothesis.
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Post-admission hematoma expansion in patients with intracerebral hemorrhage (ICH) com-
prises a simultaneous major clinical problem and a possible target for medical intervention.
In any case, the ability to predict and observe hematoma expansion is of great clinical
importance. We review radiological concepts in predicting and observing post-admission
hematoma expansion. Hematoma expansion can be observed within the first 24 h after
symptom onset, but predominantly occurs in the early hours. Thus capturing markers of
on-going bleeding on imaging techniques could predict hematoma expansion.The spot sign
observed on computed tomography angiography is believed to represent on-going bleeding
and is to date the most well investigated and reliable radiological predictor of hematoma
expansion as well as functional outcome and mortality. On non-contrast CT, the presence
of foci of hypoattenuation within the hematoma along with the hematoma-size is reported
to be predictive of hematoma expansion and outcome. Because patients tend to arrive
earlier to the hospital, a larger fraction of acute ICH-patients must be expected to undergo
hematoma expansion. This renders observation and radiological follow-up investigations
increasingly relevant.Transcranial duplex sonography has in recent years proven to be able
to estimate hematoma volume with good precision and could be a valuable tool in bedside
serial observation of acute ICH-patients. Future studies will elucidate, if better prediction
and observation of post-admission hematoma expansion can help select patients, who will
benefit from hemostatic treatment.
Keywords: intracranial hemorrhage, cerebral hemorrhage, cerebral angiography, X-ray computed tomography,
transcranial ultrasonography
BACKGROUND
Early intervention is today a growing concept in the treatment
of stroke patients. Patients arrive in the hospital early after the
onset of stroke symptoms as a consequence of treatment options
in ischemic stroke. Due to the ultra-early work-up, patients with
intracerebral hemorrhages (ICH) will often be diagnosed quickly
after symptom onset. ICH presents in general as devastating
strokes, and patients are often prone to poor outcome. This is
due to the stroke per se and the lack of treatment concepts proven
to be effective in randomized clinical trials. Recently, both surgical
intervention (1) and hemostatic therapy (2) have failed to improve
the functional outcome.
As ICH is diagnosed increasingly early, post-admission hema-
toma expansion will become a more frequent observation. Post-
admission hematoma expansion contributes to the clinical insta-
bility of the patients, but at the same time it might be a promising
target for interventions to limit final hematoma volume, save
brain tissue – and improve functional outcome. Thus, being able
to predict and dynamically observe post-admission hematoma
expansion is of paramount clinical importance. In recent years,
several radiological concepts to predict post-admission hematoma
expansion have been identified. In this review, we summarize radi-
ological predictors of hematoma expansion in patients with ICH.
We further review new imaging concepts in dynamical observation
of post-admission hematoma expansion.
POST-ADMISSION HEMATOMA EXPANSION
Post-admission hematoma expansion is defined as enlargement
of the hematoma volume between the admission imaging pro-
cedure and a later imaging procedure. A variety of definitions
of significant hematoma expansion have been proposed based
on both relative (e.g., 33%) and absolute (e.g., 6 or 12.5 mL)
hematoma volume increase. No convincing evidence exists as to
which of these definitions best discriminate patients prone to poor
functional outcome and all definitions yield equally low sensitiv-
ity (3). However, a trend might exist toward definitions based
on absolute expansion being slightly more clinically meaningful
in terms of outcome compared to definitions based on relative
expansion (3).
Studies to determine the time interval of which post-admission
hematoma expansion occur have been limited by the fact that ser-
ial radiological examinations in order to estimate the hematoma
volume are hard to perform in an unstable patient-group and
would potentially expose the patients to unacceptable amounts
of ionizing radiation. Consequently, most published studies are
limited by few prospective measurements or imprecise retrospec-
tive methodology. Studies indicate that post-admission hematoma
expansion can be observed in up to 40% of patients admitted
in an acute fashion (3). In a prospective study conducted on
patients admitted within 3 h after symptom onset Brott et al.
reported that 26% suffered hematoma expansion within the first
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hour after admission and additional 12% suffered expansion
within the following 23 h (4). Ovesen et al. reported in another
prospective study that active expansion could be observed within
the first 8 h after symptom onset in the group of patients, who
on 24 h follow-up CT-scan presented a final clinically relevant
hematoma expansion (>12.5 mL) (5). Even though the vast major-
ity of the hematoma expansion is observed to occur in the first
hours after stroke onset, evidence also indicates that it is pos-
sible for hematoma expansion to take place later on and up to
24 h (6, 7). This supports the hypothesis that hematoma expan-
sion (Figure 1) is a dynamic process with intermitting bleeding
episodes caused by not only the originally ruptured vessel, but
also by secondary rupture of adjacent vessels exposed to pres-
sure and ischemia inflicted by the hematoma mass-effect (8).
The secondary vessel rupture in the rim of the hematoma might
explain that hematoma expansion does not happen symmetrically
around the surface of the hematoma, but is located non-uniformly
(9). Further, the secondary vessel rupture and intermitting bleed-
ing episodes might also be the cause of the apparent plateau-
phases with constant hematoma volume between active expansion
episodes (5).
Post-admission hematoma expansion has been independently
associated with early neurological deterioration (4, 10), poor
functional outcome, and mortality (11, 12). An almost linear
association between hematoma expansion and the probability of
poor outcome has been reported – with 1 mL additional expansion
yielding a 5% increased risk of death and dependency (12).
FIGURE 1 | Suggested schematic model for a step-wise hematoma
expansion-profile in intracerebral hemorrhages. Phase 1 represents the
initial active bleeding-period most likely caused by the originally ruptured
vessel. If patients are admitted within this phase an active hemorrhage will
still be occurring post-admission and instant expansion can be observed.
After phase 1 a plateau-phase might exist in which the hematoma volume is
constant or active bleeding occurs slowly. In some patients, this phase
might represent the final hematoma volume (horizontal stippled line). Phase
2 represents a secondary bleeding-period. This is likely due to secondary
vessel rupture caused by pressure and ischemia on adjacent tissue
structures or by re-bleeding from the originally ruptured vessel. Some
patients might have multiple secondary bleeding-periods and some even
late (phase 3). Between these periods are interpolated plateau-phases with
relative constant hematoma volume or slow active bleeding. This results in
the final hematoma volume observed on follow-up imaging.
COMPUTED TOMOGRAPHY ANGIOGRAPHY
Post-admission hematoma expansion occurs due to leakage of
blood into an existing hematoma cavity. As previously discussed,
this process represents an on-going or intermittingly on-going
active bleeding process. Consequently, the ability to visual-
ize this process of on-going bleeding could provide us with
excellent prediction of hematoma expansion. It is an alluring
thought that this active bleeding process could be visualized using
radiographic contrast-agents, because leakage from surround-
ing vessels would be represented by pooling of contrast-material
inside the hematoma. The concept of contrast-leakage into the
hematoma in acute ICH-patients undergoing angiography dates
back more than 40 years (13). It was originally observed that
patients arriving earlier in the hospital more often demonstrated
contrast-leakage. In recent years, much attention has been placed
on the possibility of visualizing contrast-leakage using computed
tomography angiography (CTA).
CONTRAST-LEAKAGE ON CT-IMAGING
Traditionally, two interrelated marker of contrast-leakage have
been defined: the spot sign on CTA source images or max-
imum intensity projections and pooling of contrast (contrast
extravasation) in the hematoma (Figure 2).
One of the first studies on contrast extravasation in patients
with spontaneous ICH using CTA was presented by Murai et al.
(14) in 1999. The study looked at extravasation of contrast on
3D-CTA images and concluded that extravasation was linked
FIGURE 2 | Spot sign and contrast extravasation. Patient admitted
within 2 h after symptom onset. (A) Initial non-contrast CT demonstrating
small basal-ganglia hemorrhage, (B) CTA source image demonstrating
single spot sign (arrow), (C) 3-min post-contrast CT-imaging demonstrating
contrast extravasation (arrow), and (D) 24 h follow-up CT revealing final
hematoma volume.
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to hematoma expansion. Other studies have later supported
this claim, and excellent negative predictive value in predict-
ing hematoma expansion is indicated across studies performed
(Figure 3). The concept of contrast extravasation in general refers
to all manners of contrast-leakage into the hematoma. However,
in more recent studies, the concept of contrast extravasation refers
only to pooling of contrast in the hematoma on post-contrast CT-
imaging following CTA (15). In this review, contrast-leakage will
be used as an umbrella term for both contrast extravasation and
the spot sign.
Wada et al. (16) was the first to describe small enhancing foci
on CTA source images – the spot sign – and its ability to predict
hematoma expansion. Ever since, many other studies have focused
on the spot sign as a promising biomarker to predict hematoma
expansion. Among studies, slightly different definitions of the spot
sign have been used, however, many studies use definitions similar
to the one proposed by Wada et al: “one or more, 1–2 mm foci of
enhancement within the hematoma on CTA source images” or as
proposed by Delgado Almandoz et al. (17): (i) 1≥ focus of contrast
pooling within the ICH; (ii) with an attenuation≥120 Hounsfield
units; (iii) discontinuous from normal or abnormal vasculature
adjacent to the ICH; and (iv) of any size and morphology.
The overall prevalence of the spot sign varies among studies
from 19 to 41% (6, 16–24) (Figure 4). This reflects the differences
FIGURE 3 | Effect of contrast extravasation on hematoma
expansion. This figure presents the predictive values across studies for
contrast extravasation to predict hematoma expansion. The predictive
values indicated the independent effect of contrast extravasation and
not the effect of contrast extravasation in addition to spot sign – please
see text. N CE, number of patients with contrast extravasation; N all,
total number of patients in the population; exp def, definition of
hematoma expansion.
FIGURE 4 | Effect of spot sign on hematoma expansion. This figure presents the predictive values across studies for spot sign in predicting hematoma
expansion. N Sps, number of patients with spot sign; N all, total number of patients in the population; exp def, definition of hematoma expansion.
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in the definition used, different scan protocols and the time-
window utilized. In patients arriving within 3 h, the prevalence
is reported to be as high as 43–60% (6, 17) dropping down to
11% in patients presenting beyond 6 h after onset (6). This is
in good accordance with the proposed temporal profile of post-
admission hematoma expansion, because it indicates that the
majority of expansion happens within the first hours. The spot
sign has been shown to be associated with larger hematoma admis-
sion volume (17, 18, 22, 25), higher admission National Institute
of Health Stroke Scale (NIHSS) value (18), and hypertension on
admission (17, 22). Whether use of vitamin-K antagonists and
antiplatelet medication is associated with a higher prevalence of
the spot sign, varies between study-results (17, 18, 22). It has
been observed that the contrast-phase, in which CTA images were
acquired, plays a role in the prevalence of the spot sign. The preva-
lence of the spot sign was highest in the late venous phase. This
might reflect the time required for contrast to accumulate in the
hematoma (26).
Across studies, the inter-observer agreement for identifying
the spot sign is in general reported to range between good and
moderate (κ= 0.60–0.85) (16, 21, 22). In the PREDICT-study, it
was observed that even though no definition for the spot sign
was selected at the beginning of the study, the agreement in
identifying the spot sign between site-investigators and the final
expert-adjudication was substantial (κ= 0.72) (18). Huynh et al.
(27) presented a study regarding the accuracy of 131 readers to
recognize the spot sign, and it was found that physicians in gen-
eral showed a good specificity (96%), however, the sensitivity
was smaller (78%). This might be due to incorrect perception
of spot sign mimic. The study further shows that the identifi-
cation of spot sign proceeded quickly (27). The spot sign must
consequently be seen as a relatively easily recognizable biomarker.
However, physicians’ ability to recognize it can be improved by
simple learning programs (28). This adds greatly to the every-day
clinical usefulness of the spot sign in acute ICH-patients.
The spot sign has been proven to be a valid biomarker of
hematoma expansion, possibly because of its representation of foci
of active bleeding (29). The spot sign in general yields a relatively
high negative predictive value (NPV: 0.75–0.98) along with slightly
lower positive predictive value (PPV: 0.45–1.00) toward hematoma
expansion (Figure 4) (6, 16–24, 30). Sensitivity and specificity
are reported to be 0.46–0.91 and 0.84–1.00, respectively (6, 16–
24). This is true, even though studies report patients included
in different time intervals after ictus. Brouwers et al. (6) found
that the positive and negative predictive value remained relatively
constant in patients admitted 0–3, 3–6, and >6 h after symptom
onset. This indicates the overall ability of the spot sign to predict
hematoma expansion across various time-windows. Differences
in imaging protocols might also affect the ability of the spot sign
to predict hematoma expansion. Spot sign observed in the peak
arterial contrast-phase might entail a larger absolute hematoma
expansion volume compared to spot sign observed in later venous
phases (26). The effect of the spot sign on hematoma expansion is
observed to be independent from other predictors of hematoma
expansion – especially vitamin-K antagonist use and hematoma
volume (16–18, 22) even through the factors might complement
each other. In a recently proposed prognostic score, time to initial
CT-scan, initial hematoma-size, CTA spot sign, and pre-stroke
warfarin treatment were included in order to enable a better strati-
fication of patients with regard to the likelihood of post-admission
hematoma expansion (31).
Different amendments to the spot sign have been proposed to
increase its ability to identify patients prone to hematoma expan-
sion. Besides the spot sign observed on CTA source images, delayed
post-contrast sequences have been utilized to visualize contrast
extravasation. Two small studies indicate that the presence of both
spot sign and post-contrast extravasation increases the likelihood
of hematoma expansion compared to the spot sign alone (19, 20).
Another related add-on to the spot sign is the so-called tail-sign
(32). The tail-sign is observed originating from the M1 segment
of the middle cerebral artery on coronal CTA images in patients
with a basal-ganglia hemorrhage and is thought to represent active
bleeding from the striate arteries. Only a single smaller study has
elaborated the tail-sign, and additional work is needed to confirm
its validity.
SPOT SIGN SCORE
The spot sign score (SSS) was originally proposed by Delgado
Almandoz et al. (17) in an attempt to systematically characterize
the spot sign and develop a scale capable of predicting hematoma
expansion better than the spot sign per se was able to. The result-
ing SSS is presented in Table 1. In the original study, the score
provided excellent discriminative capability, when it comes to
hematoma expansion (AUC-ROC 0.93 CI: 0.89–0.95), and the risk
of hematoma expansion (>30% or 6 mL) increased from 2% in
the group with a SSS of 0 to 100% in patients with a SSS of four.
Patients with spot sign on admission that arrived in hospital earlier
in general presented with a higher SSS compared to patients, who
arrived later. The authors later demonstrated that the SSS inde-
pendently predicts in-hospital mortality and 3 months outcome
in an almost linear manner (when increasing from SSS 0 to 4, in-
hospital mortality increased from 24 to 75% – and mean 90 days
mRS from 3.2 to mRS 5.4) (33).
Other studies have confirmed the independent capability of SSS
to predict hematoma expansion (21, 23, 34), mortality, and poor
outcome (21, 23) along with the almost linear increase in risk of
poor functional outcome with increasing SSS (23). However, not
all studies have confirmed that SSS contained superior predictive
Table 1 | Spot sign score.
Spot sign characteristics Points
Number of spot signs
1–2 1
≥3 2
Maximal axial dimension
1–4 mm 0
≥5 mm 1
Maximum attenuation
120–179 HU 0
≥180 HU 1
Replicated from Delgado Almandoz et al. (17).
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capabilities of discriminating patients prone to hematoma expan-
sion and poor outcome compared to the spot sign per se (21, 34).
This might suggest that much of the predictive capability of the SSS
is contained within the demonstration of the spot sign. This was
emphasized in a post hoc analysis from the PREDICT-study reveal-
ing no differences between the discriminative capability toward
hematoma expansion of the number of spot signs demonstrated
and the SSS (34). It was further demonstrated that the risk of
hematoma expansion did not increase significantly with increasing
SSS. In contrast to this, the risk of hematoma expansion increased
significantly with increasing number of spot signs present. The
authors speculate that the reason for these differences is that the
attenuation of the spot sign – which was proven to have good
discriminative ability, when it comes to hematoma expansion in
single center studies – might vary between different CT-scanner
manufactures along with differences in contrast administration
protocol (34).
All in all, the SSS would – if proven valid – provide a better pre-
diction of hematoma expansion useful in clinical decision-making
and clinical trials, but so far, the general validity is questionable.
However, due to the relative complexity of obtaining the score
compared to the spot sign per se or number of spot signs, it might
represent a less relevant tool in every-day clinical practice and
outside clinical trials.
RELATIONSHIP BETWEEN CONTRAST-LEAKAGE AND OUTCOME
Both the spot sign and contrast extravasation have been shown to
be associated with poor outcome. The predictive values are pre-
sented in Table 2 for in-hospital mortality, 90 days mortality and
90 days functional outcome.
The presence of contrast-leakage on admission is associated
with short-term clinical outcome (Table 2). It has been shown
that the presence of spot sign on admission CTA is linked to
neurological deterioration within the first 24 h after symptom
onset (18, 35). Across studies, a clear trend toward high neg-
ative predictive values of in-hospital mortality was identified,
however, with relatively modest or poor positive predictive val-
ues (16, 21–23, 33, 36, 37). All in all, the absence of contrast
extravasation or spot sign indicates an overall increased stabil-
ity of the patient during the acute phase of illness. This might
be an important observation, as it appears that the difference in
mortality between spot sign positive and negative patients mani-
fests during the initial days after symptom onset. After the initial
period, the mortality-rate appears to become even between the
two groups (18, 38).
The absence of the spot sign in general is associated with good
negative predictive values, when it comes to 3 months mortality
(18, 21, 22). The spot sign independently increases the probability
of long-term fatality (18, 21, 38) and poor functional outcome
3 months after admission in most studies (21, 23, 33, 38). The
patients with spot sign in general present a higher 3-month modi-
fied Rankin scale score compared to patients without – indicating
poorer functional rehabilitation outcome (18, 38). However, in a
recent prospective study, this association could not be replicated
(22). This finding could represent local variations in treatment
and rehabilitation efforts.
NON-CONTRAST COMPUTED TOMOGRAPHY
Non-contrast computed tomography (NC-CT) remains the radio-
logical investigation of choice conducted, when stroke patients are
admitted for fibrinolysis work-up. Simple and broadly validated
predictors of post-admission hematoma expansion observed on
NC-CT are therefore essential, because this can potentially predict
clinical instability and poor long-term functional outcome.
HEMATOMA-SIZE
For a long period of time, the initial admission hematoma volume
has been recognized as a major determinant of outcome in patients
with acute ICH. In a classic study elaborated by Broderick et al.
(39), it was demonstrated that the 30-day mortality in patients
with basal-ganglia hemorrhage and a volume above 60 mL was as
high as 93% dropping down to 23% for volumes below 30 mL. A
similar pattern was observed for patients with lobar hemorrhages.
Other studies have replicated these findings and added other
measurements of outcome to the predictive capability of the ini-
tial hematoma volume (e.g., in-hospital mortality (40), functional
outcome and mortality (40–44), long-term survival (45)), and ini-
tial hematoma volume features in most clinical grading scores
concerning ICH-patients (46). Hematoma volume and clinical
neurological status score on admission (Glasgow Coma Scale,
NIHSS, or Canadian Stroke Scale) in general compete for being
among the most powerful predictors of outcome.
In the context of acute demonstration of ICH, the natural
questions to be raised are: (1) what volume is the most predic-
tive – the early volume with possible on-going hemorrhage or the
final hematoma volume? (2) Is it safe to assume that a patient, who
arrives early in the hospital and demonstrates a small hematoma
volume, is clinically stable and prone to good outcome? 3) What
can the hematoma volume tell us about the expansion-potential
of the patient?
In an analysis from the VISTA-database (47) on patients pre-
senting with ICH within 6 h after ictus, it was demonstrated that
patients with an initial hematoma volume below 20 mL were sig-
nificantly less likely to undergo hematoma expansion compared to
a hematoma volume above 30 mL (using the 12.5 mL expansion-
definition). The observation that smaller hematomas are more
stable is supported by data from the Recombinant Activated Factor
VII ICH Trial (48, 49) along with other individual publications (50,
51). In addition to a decreased rate of post-admission hematoma
expansion, smaller hematomas are in general associated with a
lower likelihood of early neurological deterioration – and thus a
more stable acute course of illness (35, 47, 52).
In a most interesting study elaborated by Rodriguez-Luna et al.
(35), the hematoma volume was divided by the time from ictus to
admission, yielding an ultra-early hematoma growth pace. It was
demonstrated that a higher growth pace was independently associ-
ated with the occurrence of post-admission hematoma expansion,
early neurological deterioration and poor long-term functional
outcome. The discriminative capability of hematoma growth pace
was better compared to absolute volume on admission toward
early neurological deterioration and poor long-term functional
outcome. This method could potentially solve some of the previ-
ous proposed uncertainties on the predictive value of hematoma
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Table 2 | Effect of contrast-leakage in predicting outcome.
Design Extravasation
sign
No. contrast-leakage
positive (%)
Total number
participating
Time-frame Outcome Sensitivity (%) Specificity (%) PPV (%) NPV (%)
In-hospital mortality
Becker et al. (36) Retrospective Contrast
extravasation
52 (46) 113 All patients Hospital fatality 77 73 63 84
Goldstein et al. (37) Retrospective Contrast
extravasation
58 (56) 104 All patients Hospital fatality 73 50 33 85
Wada et al. (16) Retrospective Spot sign 13 (33) 39 All patients Hospital fatality 43 69 23 85
Delgado Almandoz et al. (33) Retrospective Spot sign 133 (23) 573 All patients Hospital fatality 41 85 56 76
Li and Wang et al. (21) Prospective Spot sign 30 (22) 139 Within 6 h Hospital fatality 60 81 20 96
Romero et al. (23) Prospective Spot sign 31 (24) 131 All patients Hospital fatality 68 88 61 91
Rizos et al. (22) Prospective Spot sign 27 (27) 101 Within 6 h Hospital fatality 47 77 26 89
90-days mortality
Li and Wang et al. (21) Prospective Spot sign 30 (22) 139 Within 6 h Case fatality 50 82 27 93
Demchuk et al. (18) Prospective Spot sign 53 (25) 211 Within 6 h Case fatality 43 81 43 80
Rizos et al. (22) Prospective Spot sign 27 (27) 101 Within 6 h Case fatality 29 74 26 77
90-days outcome
Delgado-Almandoz et al. (33) Retrospective Spot sign 133 (23) 573 All patients mRS>3a 23 89 51 70
Li and Wang et al. (21) Prospective Spot sign 30 (22) 139 Within 6 h mRS>2 36 94 87 58
Romero et al. (23) Prospective Spot sign 31 (24) 131 Within 24 h mRS>3a 34 94 90 50
Havsteen and Ovesen et al. (38) Prospective Spot sign 37 (29) 128 Within 4.5 h mRS>4 60 86 68 81
aBased on the surviving patients at 3months.
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volumes in patients with early presentation due to possible on-
going hemorrhage, and the method needs validation in broader
populations.
INTRAVENTRICULAR HEMORRHAGIC EXTENSION
Intraventricular hemorrhagic extension is a frequent finding in
patients admitted with acute ICH. In patients admitted earlier than
3 h after symptom onset, intraventricular hemorrhagic extension
(IVH) is present in 31–48% (22, 35, 38, 53, 54), but delayed IVH
can be detected, on follow-up imaging, in up to 20% (53, 54) of
the patients without IVH on admission. This is a consequence of
post-admission hematoma expansion decompressing into the low
resistance ventricular system.
The anatomical location of the intracerebral hematoma is an
important determinant for the probability of IVH. Hematomas
located in the thalamus or the caudate nucleus will more often
extend into the ventricular system due to the proximity (53–57)
compared to lobar hematomas. Hallevi et al. (56) calculated for
each anatomical position a volume range (decompression range),
below which IVH was very unlikely, however, if ICH volume grew
above this range, IVH was very likely. This range was very nar-
row for hematomas located in the thalamus (7.0–12.7 mL) and
pons (4.3–11.2 mL) but considerably wider for lobar hematomas
(15.4–70.7 mL). This implicates that if a patient with thalamic or
pontine hemorrhage without IVH is admitted early after symp-
tom onset or display radiological predictors of active bleeding on
admission CT, later re-scan should be considered due to a high
probability of delayed IVH. The decompression ranges might also
explain the fact that patients with IVH in general present signifi-
cantly higher admission hematoma volumes compared to patients
without (54, 57).
Whether the presence of IVH is associated with hematoma
expansion is controversial. Most studies do not find an association
between hematoma expansion and IVH, however, one study has
shown that lenticular and lobar hematomas with accompanying
IVH displayed a higher proportion of hematoma expansion (54).
This could be explained by the fact that the expansion-potential
is high in a non-periventricular hematoma, if it is able to break
through to the ventricles. This finding needs validation in further
studies.
Intraventricular hemorrhagic extension may be viewed as a
separate hematoma, and expansion of the intraventricular blood
volume can occasionally be observed. Steiner et al. (57) reported
that 12% of patients with initial IVH suffered enlargement of the
IVH volume between baseline and follow-up scan. This expan-
sion was associated with higher baseline ICH hematoma volume,
elevated blood-pressure and short time from symptom onset to
admission scan. Expansion of the IVH volume was independently
associated with poor functional outcome and death.
Intraventricular hemorrhagic extension is reported to be inde-
pendently associated with both early (<48 h after onset) (10, 35,
58) and late (48 h–1 week after onset) (59) neurological dete-
rioration. There is a high load of evidence indicating that the
presence of IVH is independently related to poor clinical out-
come and mortality (43, 45, 60–62) mainly due to the obstruc-
tion of cerebrospinal fluid flow and hydrocephalus (55, 63),
but also by other mechanisms. The association with mortality
and poor outcome is likely related to the severity of the IVH
volume (57, 61, 64).
HEMATOMA HETEROGENICITY (SWIRL-SIGN) AND IRREGULARITY
It is a frequent observation that patients with ICH present
hematomas in various shapes and with heterogeneous attenuation
on NC-CT. It has for a long period of time been a puzzling hypoth-
esis that this could potentially predict the risk of post-admission
hematoma expansion due to the fact that this may signify on-going
bleeding.
The observation that a heterogenic attenuation of the
hematoma on NC-CT represents on-going bleeding originally
descends from observations of patients with epidural hematomas
(65). It was observed that the finding of a zone of hypoattenuation
within the hyperattenuated hematoma – the so-called “Swirl-
sign” – correlated to active bleeding (66). The theory that the
swirl-sign could represent on-going bleeding was founded on early
studies using computed tomography techniques demonstrating
that coagulated and retracted blood-clots appear hyperattenuated
compared to normal brain tissue. When blood coagulates, it expels
low-density serum leaving behind a high concentration of red
blood cells – and thus the globin-protein responsible for the high
attenuation (67). Consequently, if a hematoma contains a mixture
of coagulated (hyperattenuation) and uncoagulated blood (hypo-
or isoattenuation), it appears heterogenic on a NC-CT.
A number of studies have applied the same principle on patients
with acute ICH. Definitions of a heterogeneous attenuation (swirl-
sign) (Figure 5) vary between studies, however, a clinically relevant
and potentially every-day useful definition proposed by Selariu
et al. yielded good intra- and inter-observer agreement: swirl-
sign was defined as regions of hypoattenuation or isoattenuation
(compared to the attenuation of surrounding brain-parenchyma)
within the hyperattenuated ICH (68).
A study elaborated by Barras et al. on patients included on the
placebo arm of the Recombinant Activated Factor VII ICH Trial
reported that hypoattenuated foci on the admission scan indepen-
dently predicted some definitions of hematoma expansion, even
after adjustment for other predictors of hematoma expansion (48).
Additional studies have later confirmed this observation (51, 69).
The presence of heterogeneity is further linked to mortality and
poor functional outcome (68).
It has been shown that patients arriving in the hospital early
have a higher probability of presenting a heterogeneous attenua-
tion of the hematoma. This fits well with the observations of the
timing of post-admission hematoma expansion. In one study, the
prevalence dropped from 36% in patients arriving within 2 h to
13% in patients arriving later that 24 h after symptom onset (68).
The relationship between the swirl-sign and the spot sign would
be of pathophysiological and clinical interest and remains to be
investigated.
Another proposed marker of active bleeding is irregular shape
of the hematoma. The hypothesis behind this observation is that
the irregularity could result from multiple leaking vessels feed-
ing the hematoma and hence a higher probability of hematoma
expansion (70). Even though the observation that irregularity of
the hematoma shape should facilitate hematoma expansion is val-
idated in a large study elaborated by Fujii et al. (71), other studies
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FIGURE 5 | Heterogenicity on admission NC-CT. Admission and follow-up radiology on two patients admitted with acute ICH. NC-CT (A,D) demonstrates
marked heterogenic attenuation in hematoma appearance. Arrow on (D) marks swirl-sign. On (B,E) both patients present spot sign. After 24 h (C,F) both
patients present enlargement of the hematoma volume and midline shift.
have not been able to confirm this finding – thus making irregular
shaping of the hematoma an uncertain predictor of hematoma
expansion (48, 51, 69).
FOLLOW-UP IMAGING IN PATIENTS WITH INTRACEREBRAL
HEMORRHAGE
In relation to the substantial amount of patients undergoing post-
admission hematoma expansion and the trend toward shorter
interval between symptom onset and admission imaging, the
need for follow-up imaging after the acute phase of illness
becomes more crucial (72). In general, follow-up NC-CT 24 h
post-admission is implemented in many centers to evaluate the
final hematoma volume, midline shift, the presence of intraven-
tricular or subarachnoid extension of the hemorrhage, and edema
formation. NC-CT is in general viewed as the gold standard, when
it comes to demonstrating and measuring the volume of ICH.
However, CT is limited by the utility of ionizing radiation making
it unsuitable for serial assessments of the hematoma volume. In
addition, the patients have to leave the stroke wards in most centers
in order to undergo CT-studies.
In recent years, the concept of transcranial duplex sonography
(TCDS) has become available to dynamically follow the progres-
sion of the intracerebral hematoma on B-mode ultrasound images.
The examination is performed through the trans-temporal bone
window (Figure 6). On B-mode images, the hematoma is visu-
alized as a hyperechogenic structure compared to surrounding
brain-parenchyma. The hematoma is often visualized through the
contralateral bone window in reference to the hematoma loca-
tion (73) (Figure 7). The volume of the hematoma is obtained
by measuring the sagittal, transversal, and coronal diameter of the
hematoma and then calculating the volume using the standard
formula: ABC/2 (74, 75) (Figure 7). Studies indicate that TCDS
is able to identify ICH with good sensitivity (73, 75–79). TCDS is
also able to estimate the diameters of the hematoma with system-
atic deviation close to zero (75, 76) and good volume estimation
compared to CT (75–77). Studies further indicate that TCDS is
useful in following hematoma expansion (75) and demonstrating
the presence of IVH (73, 77). In patients with hematomas that are
difficult to visualize on TCDS, the administration of ultrasound
contrast might improve precision of the estimated volume (78).
Midline shift can also dynamically be followed using TCDS by
measuring the distance from the transducer to the third ventri-
cle bilaterally (77, 80, 81). The third ventricle is normally easily
recognized on TCDS (Figure 7). By adding Doppler flow studies
of the intracranial vessels, TCDS might also be able to estimate
intracranial pressure (82, 83), however, additional work needs to
examine this in greater detail.
The major limitation to TCDS in patients with ICH is that not
all patients present with trans-temporal acoustical bone windows
sufficient to allow penetration of diagnostic ultrasound waves. The
proportion of the study populations without an acoustical window
varies from 7 to 56% in studies on ICH-patients, even though most
studies report approximately 20% failure-rate (73, 75, 76, 78, 81,
83). The most notorious predictors of lack of an acoustical window
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are gender (women in general present poorer acoustical windows),
increasing age, and thickness of scull (84, 85). In addition, peo-
ple of Asian descent in general present with a higher prevalence
of inadequate trans-temporal acoustical bone windows compared
FIGURE 6 |Trans-temporal ultrasound window. Approximate location of
the trans-temporal ultrasound window.
to Caucasians (76, 84). TCDS is further limited by the anatomi-
cal location of the hematoma. Volume estimation of hematomas
located either high cortical or infratentorial can be troublesome
due to its position in relation to the trans-temporal bone window
(73, 75, 77).
Even with the presented limitations, evidence suggests the
usefulness of TCDS in patients with ICH as an add-on to the
consecutive clinical surveillance during the acute phase of illness.
CONCLUSION
Post-admission hematoma expansion in patients with ICH con-
tributes to the clinical deterioration, but may also contain an
attractive target for early intervention. CTA for the purpose of
evaluating underlying vascular pathology and presence or absence
of the spot sign should be considered in all acute ICH-patients.
The spot sign has been shown to be a promising biomarker of post-
admission hematoma expansion with good predictive capability.
In patients with contraindications to CTA predictors of on-going
hemorrhage are available for NC-CT. The presence of spot sign,
swirl-sign, IVH, or a large hematoma on admission scan marks
the patient as potentially clinical unstable and as subject for inten-
sified clinical observation and follow-up imaging. Predictors of
hematoma expansion also contain prognostic information toward
long-term functional outcome and mortality. TCDS provides a
new method to consecutively monitor the development of the
hematoma bedside. On-going and future studies will elucidate,
if selection of patients for hemostatic therapy based on radio-
logical predictors of post-admission hematoma expansion will
finally provide us with an effective treatment-offer for patients
with ICH.
FIGURE 7 |Transcranial duplex sonography-images of
basal-ganglia hemorrhage. A patient with basal-ganglia ICH. On axial
images (A,B) the hematoma can be observed as a hyperechogenic
region in the middle of the picture. The rim of the hematoma is marked
by black on (C). In addition on (C) the location of important midline
landmark structures as the pineal gland and the third ventricle are
marked. (D,E) Are coronal images. On (F) the lateral ventricles, the
third ventricle, and the hematoma is marked.
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